

PRIMER

How to make a midbrain dopaminergic neuron

Ernest Arenas^{1,*}, Mark Denham^{1,2} and J. Carlos Villaseca^{1,3}

ABSTRACT

Midbrain dopaminergic (mDA) neuron development has been an intense area of research during recent years. This is due in part to a growing interest in regenerative medicine and the hope that treatment for diseases affecting mDA neurons, such as Parkinson's disease (PD), might be facilitated by a better understanding of how these neurons are specified, differentiated and maintained *in vivo*. This knowledge might help to instruct efforts to generate mDA neurons *in vitro*, which holds promise not only for cell replacement therapy, but also for disease modeling and drug discovery. In this Primer, we will focus on recent developments in understanding the molecular mechanisms that regulate the development of mDA neurons *in vivo*, and how they have been used to generate human mDA neurons *in vitro* from pluripotent stem cells or from somatic cells via direct reprogramming. Current challenges and future avenues in the development of a regenerative medicine for PD will be identified and discussed.

KEY WORDS: Dopamine neurons, Midbrain, Parkinson's disease, Regeneration, Reprogramming, Stem cells

Introduction

Dopaminergic (DA) neurons are capable of releasing dopamine, a catecholaminergic neurotransmitter. They are characterized by the presence of tyrosine hydroxylase (TH), the rate-limiting enzyme in the synthesis of catecholamines, and are found throughout the mammalian central nervous system, including the ventral midbrain (VM) (Björklund and Hökfelt, 1983). Midbrain DA (mDA) neurons are arranged in three distinct nuclei: the *substantia nigra pars compacta* (SNc, also known as the A9 group), the ventral tegmental area (VTA, or A10 group) and the retrorubral field (RrF, or A8 group) (Björklund and Hökfelt, 1983; Dahlstroem and Fuxe, 1964) (Fig. 1A). Different populations of mDA neurons project to distinct areas and control or modulate specific functions, according to their targets [reviewed by Roeper (2013)]. VTA and RrF DA neurons project to the ventromedial striatum (*nucleus accumbens*), parts of the limbic system and prefrontal cortex, forming the mesolimbic and mesocortical systems (Fig. 1B). These neurons regulate emotional behavior, natural motivation, reward and cognitive function, and are primarily implicated in a range of psychiatric disorders (Carlsson, 2001; Chao and Nestler, 2004; Hornykiewicz, 1978). By contrast, DA neurons located in the SNc primarily project to the caudate-putamen, the dorsolateral

striatum, forming the so-called nigrostriatal pathway, which predominantly regulates motor function and degenerates in Parkinson's disease (PD) (Box 1; Fig. 1A and B, in pink). This disorder was first described clinically by the British physician James Parkinson in 'An Essay of the Shaking Palsy' published in 1817 (Horowski et al., 1995). However, it was only many years later that the pathological basis for PD was found to relate to the degeneration of SNc neurons (Foix and Nicolesco, 1925; Graham, 1979; Hassler, 1938) and the loss of dopaminergic innervation of the striatum (Lloyd and Hornykiewicz, 1970). We now know that PD involves the degeneration of multiple neuronal subtypes besides SNc neurons (Jellinger, 1991). However, the cells that are most affected and responsible for many of the motor features in PD are mDA neurons of the SNc, a cell type that has become a primary target for cell replacement therapy (Box 1). Our ability to generate subtype-specific human mDA neurons *in vitro* might therefore hold the key for the development of future regenerative medicine for PD.

Transplantation of human fetal midbrain tissue in open-label clinical trials, in which both the researcher and the test subject know what treatment is administered, has provided proof of concept for cell replacement therapy in PD (Arenas, 2010; Evans et al., 2012; Hallett et al., 2014; Lindvall and Björklund, 2004, 2011). However, logistical and ethical difficulties in performing such studies using human fetal tissue have led to the search for more amenable cell preparations that could be standardized for quality, safety and functionality, prior to clinical use in PD. Human mDA neurons have been generated from multiple cell types *in vitro*, including neural stem/progenitor cells (NS/PCs) (Maciaczyk et al., 2008; Riaz et al., 2002; Ribeiro et al., 2012; Sanchez-Pernaute et al., 2001), pluripotent stem cells (PSCs) (Denham et al., 2012; Grealish et al., 2014; Kirkeby et al., 2012; Kriks et al., 2011; Xi et al., 2012) and by lineage reprogramming of somatic cells such as fibroblasts (Caiazzo et al., 2011; Kim et al., 2011; Pfisterer et al., 2011). The *in vivo* functional capacity of PSC-derived mDA cells has recently been found to match that of fetal tissue (Grealish et al., 2014). Achieving cell preparations enriched for fully functional human SNc DA neurons *in vitro* and capable of selectively re-innervating the dorsal striatum or reconstructing the nigrostriatal pathway is thus the next challenge. In order to take advantage of the therapeutic potential that stem cells and reprogramming technologies currently offer, we must improve our knowledge of the molecular mechanisms that control mDA neuron development and use this to guide strategies to generate SNc DA neurons and improve functionality *in vivo*.

In this Primer article, we discuss recent advances in understanding mDA neuron development *in vivo*, and how these developmental principles have and continue to influence the development of stem cell therapies. We also outline the challenges and opportunities that lie ahead in order to efficiently generate safe and functional human mDA neuron preparations for cell replacement therapy, as well as for disease modeling and drug discovery.

¹Laboratory of Molecular Neurobiology, Dept. Medical Biochemistry and Biophysics, Center of Developmental Biology for Regenerative Medicine, Karolinska Institutet, Stockholm 171 77, Sweden. ²Danish Research Institute of Translational Neuroscience, Nordic EMBL Partnership for Molecular Medicine, Aarhus University, Aarhus 8000, Denmark. ³Institute of Experimental Biology, Faculty of Science, Masaryk University, Brno 61137, Czech Republic.

*Author for correspondence (ernest.arenas@ki.se)

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0/>), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.




Fig. 1. Distribution of mDA neurons, their projections in the adult mouse brain and the expression of genes important for their development. (A) Coronal section of the adult brain at the midbrain level, showing the position of the three mDA nuclei: RrF/A8, SNc/A9 and VTA/A10. (B) Sagittal view of the adult brain with a schematic representation of mDA neurons and their projection areas. A8, retrobulbar; A9, substantia nigra; A10, ventral tegmental area; A8+A10, structures innervated by A8 and A10; A8-A10, structures innervated by A8, A9 and A10; ACC, anterior cingulate cortex; CNA, central nucleus of the amygdala; DS, dorsal striatum; ERC, entorhinal cortex; H, habenula; HC, hippocampus; LC, locus coeruleus; LS, lateral septum; NA, nucleus accumbens; OT, olfactory tubercle; PFC, prefrontal cortex; PRC, perirhinal cortex; PC, piriform cortex. (C,D) Sagittal view of an E11.5 mouse embryo, showing the expression of transcription factors and morphogens important for VM patterning in relation to *Th* expression. D, diencephalon; H, hindbrain; IsO, isthmus organizer; M, midbrain; T, telencephalon. (E) Coronal section through the VM at the level shown by arrows in D. BP, basal plate; mFP, midbrain floor plate.

mDA neuron development

During gastrulation, a posterior-to-anterior migration of cells takes place at the same time as the three germ layers (mesoderm, endoderm and ectoderm) are formed. At the rostral end of the embryo, the inhibitors DKK1 (dickkopf 1, a WNT inhibitor), NOG (noggin, a BMP inhibitor), LEFTY1 (left-right determination factor 1, a NODAL inhibitor) and CERBERUS (a multifunctional inhibitor of Wnt, BMP and Nodal), which suppress posterior signals and pattern the neural ectoderm, leading to the formation of the anterior neural tube (reviewed by Takaoka et al., 2007). As the development of the neural tube proceeds, two signaling centers are formed: the isthmus organizer (IsO), which defines the midbrain-hindbrain boundary (MHB) (Joyner et al., 2000; Rhinn et al., 1998; Wassarman et al., 1997), and the floor plate (FP), which controls ventral identities (Placzek and Briscoe, 2005) (Fig. 1C). During these and subsequent developmental stages, the combined action of transcription factors and morphogens from the IsO and the FP orchestrate multiple functions, including the regional identity of the VM, the specification and proliferation of mDA progenitors, mDA neurogenesis, as well as the differentiation and survival of mDA neurons.

Transcriptional regulation of VM patterning

One of the earliest and most crucial patterning events in the neural tube is the formation of the IsO at the MHB, which starts at E7.5

through the coordinated expression and mutual repression of the transcription factors, *Otx2* (orthodenticle homolog 2) in the midbrain and *Gbx2* (gastrulation brain homeobox 2) in the hindbrain, (Fig. 1C) (Broccoli et al., 1999; Millet et al., 1999; Wassarman et al., 1997). *Otx2* and *Gbx2* control the patterning of the MHB by regulating the expression of two morphogens, *Wnt1* (wingless-int1; wingless-type MMTV integration site family, member 1 – Mouse Genome Database) in the midbrain and *Fgf8* (fibroblast growth factor 8) in the hindbrain (Joyner et al., 2000; Rhinn et al., 1998) (Fig. 1D and Fig. 2, yellow area). Whereas *Otx2* is required for the expression of *Wnt1* (Puelles et al., 2004; Rhinn et al., 1999), the induction of *Fgf8* requires *Pax2* (paired homeobox 2) and is maintained by *Gbx2* (Ye et al., 1998). Importantly, *Fgf8*, but not *Wnt1*, is required (Chi et al., 2003) and sufficient (Martinez et al., 1999) for the induction of the IsO. Accordingly, cells at the MHB acquire anteroposterior information by interpreting the concentration gradient generated by the secretion of FGF8 in the IsO. Whereas high concentrations of FGF8 in the hindbrain drive a hindbrain cell fate, lower concentrations in the neighboring anterior tissue ensure that the cells adopt a midbrain identity (Basson et al., 2008; Sato and Nakamura, 2004; Suzuki-Hirano et al., 2005). In agreement with this, FGF8 can induce mDA neurons in brain explants, at a certain distance from the FGF8 source (Ye et al., 1998), by a process that requires *Wnt1* (Prakash et al., 2006)

Box 1. Parkinson's disease and its treatment

Parkinson's disease (PD) is a progressive neurodegenerative disorder, characterized by the loss of mDA neurons of the SNc that project to the striatum (Fig. 1A,B). These neurons control motor behavior, and, as they degenerate, they result in several motor features of the disease, such as bradykinesia, rigidity, resting tremor, gait disturbances and postural instability (Lees et al., 2009). However, other cell types are also progressively affected in PD, such as *locus coeruleus* noradrenergic neurons (Hassler, 1938), basal forebrain cholinergic neurons (Tagliavini et al., 1984), peptidergic neurons (Agid et al., 1986) and serotonin neurons (Calabresi et al., 2013; Chaudhuri et al., 2006; Chaudhuri and Schapira, 2009; Fox et al., 2008; Halliday et al., 2011). The loss of these neurons results in non-motor features, including cognitive, affective, sleep, olfactory and intestinal alterations (Chaudhuri et al., 2006; Chaudhuri and Schapira, 2009).

The main treatment for PD is pharmacological. The most efficient drug is the dopamine precursor levodopa (Brichta et al., 2013), but other agents, including dopamine agonists, catechol-o-methyl-transferase (COMT) and monoamine oxidase type B (MAOB) inhibitors, as well as non-dopaminergic agents, such as antidepressants or cholinesterase inhibitors for dementia, are also prescribed (Connolly and Lang, 2014). The chronic use of levodopa is associated with motor complications, including fluctuations and dyskinesias (Stern et al., 2004; Weiner, 2004), whereas dopamine agonists can cause behavioral alterations (Jankovic and Aguilar, 2008). Deep brain stimulation (DBS), targeting the thalamus, subthalamic nucleus and globus pallidus, is currently used in PD patients whose motor symptoms cannot be adequately controlled by medication. The mechanism of action is not known, but DBS is thought to block depolarization, activate inhibitory neurons, desynchronize tremorogenic pacemakers and functionally disrupt neuronal networks (Jankovic and Poewe, 2012).

Although all these treatments relieve some symptoms of PD, they do not slow down disease progression or reverse the damage to mDA neurons, and the treatment loses efficacy. Cell replacement therapy has thus gained interest as a therapeutic option, as it has the potential to change the course of disease.

(Fig. 2, yellow and blue). Notably, *Wnt1* expression at the MHB is required for the development of both posterior midbrain and anterior hindbrain (McMahon and Bradley, 1990; McMahon et al., 1992; Thomas and Capocchi, 1990), but its anterior expression in two paramedial bands within the midbrain FP (Fig. 1E) serves an additional, crucial role in the specification and differentiation of mDA progenitors [reviewed by Arenas (2014)].

A second major event is the patterning of the neural tube by the morphogen SHH (sonic hedgehog) (Roelink et al., 1995). SHH, initially secreted by the notochord specifies the most ventral region of the neural plate, the FP, by inducing the expression of *Foxa2* at E8 in mice (Ang et al., 1993; Sasaki et al., 1997). *Foxa2* plays a central role in the SHH network and is required for notochord and FP development as well as for ventral patterning (Ang and Rossant, 1994; Weinstein et al., 1994). By E8.5, the FP itself starts expressing *Shh* and becomes a secondary ventral organizer of the neural tube (Fig. 1C–E). A gradient of SHH from the FP regulates patterning in the ventro-dorsal axis: ventral progenitors exposed to higher concentrations of SHH respond by expressing different transcription factors compared with dorsal cells, exposed to lower concentrations, resulting in different ventro-dorsal identities (Briscoe and Ericson, 1999; Chiang et al., 1996; Ericson et al., 1996; Marti et al., 1995; Roelink et al., 1995). SHH regulates transcription by binding to its receptor PTCH1 (patched 1), which then releases its inhibition on a co-receptor, SMO (smoothened), that signals to prevent the processing of the GLI (glioma-associated oncogene) transcription factors GLI1 and GLI2 into repressors.

Thus, *Shh* biases the balance of GLI processing towards an activated state, leading to the upregulation of ventrally expressed homeodomain transcription factors. In the midbrain FP, high SHH signaling upregulates *Foxa2* (Sasaki et al., 1997) (Fig. 2, pink area), whereas, in the basal plate (BP), a more lateral and dorsal position flanking the FP, lower levels of SHH upregulate *Nkx6-1* and *Otx2* (*Nkx* for NK homeobox protein) (Fig. 2, green area). FOXA2 also induces *Nkx6-1* in the BP (Nakatani et al., 2010) and suppresses *Nkx2-2* in the midbrain FP (mFP) (Ferri et al., 2007). Moreover, FOXA2 directly represses *Gli1-3* and upregulates *Shh* expression (Metzakopian et al., 2012). Overall, these studies indicate that ventral patterning involves both a temporal and spatial responses to SHH signaling.

Specification of mDA progenitors and suppression of lateral fates

Fate mapping experiments have indicated that mDA neurons originate from progenitors sorted for the FP marker CORIN (Ono et al., 2007) or expressing the radial glia marker *Glast/Slc1a* (glial high affinity glutamate transporter) (Bonilla et al., 2008). This shows that mFP radial glial cells, unlike FP radial glia in other brain regions, can undergo neurogenesis and are mDA progenitors. Additionally, mDA neurons have been fate-mapped from progenitors expressing *Shh* (Blaess et al., 2011; Hayes et al., 2011; Joksimovic et al., 2009a) or *Wnt1* (Brown et al., 2011; Yang et al., 2013a; Zervas et al., 2004), indicating that mFP radial glia are also constituents of the two main signaling centers, the mFP and the IsO. Moreover, information from both signaling centers is integrated in mDA progenitors, in which FOXA1/2 (Lin et al., 2009) and OTX2 (Ono et al., 2007) are present (Fig. 3) and regulate the expression of two LIM homeobox transcription factors, *Lmx1b* and *Lmx1a* (Fig. 2, blue area). Whereas *Lmx1b* is necessary for the differentiation of mDA progenitors (Smidt et al., 2000), *Lmx1a* is required for the specification of mDA neurons in the mFP (Andersson et al., 2006b; Deng et al., 2011) and, via *Msx1* (muscle segment homeobox homolog 1), to suppress the emergence of BP fates (Andersson et al., 2006a). Additionally, *Otx2* sustains the expression *Nkx6-1* in the BP and suppresses *Nkx2-2* in the mFP (Puelles et al., 2004). Thus, the concerted action of the *Shh-Foxa2* and the *Otx2-Wnt1-Lmx1a/Msx1* networks is essential not only for the specification of the mFP but also for the suppression of alternative neural fates (Fig. 2, green area).

In other parts of the neural tube, *Wnt1/β-catenin (Ctnnb)*, *Lmx1a* and *Lmx1b* are typical dorsal roof plate genes (Millonig et al., 2000; Shimamura et al., 1994). However, in the mFP, they form a positive autoregulatory loop (Chung et al., 2009) (Fig. 2, red arrows) required for mDA specification: on one hand *β-catenin* directly upregulates *Lmx1a* and *Otx2*, and, on the other hand, *Lmx1a/b* directly upregulate each other as well as *Wnt1*, *Msx1* and two key genes involved in mDA neuronal differentiation and survival, *Nurr1* (*Nr4a2*, nuclear receptor 4a2) and *Pitx3* (pituitary homeobox 3, or paired-like homeodomain transcription factor 3). Accordingly, deletion of both *Lmx1a* and *Lmx1b* results in a near-complete loss of mDA neurons (Yan et al., 2011). Similarly, deletion of *Wnt1* results in the loss of *Lmx1a*, *Nurr1* and *Pitx3* in the mFP and a complete loss of mDA neurons (Andersson et al., 2013; Prakash et al., 2006). Combined, these results indicate that the specification of mDA neurons is controlled by the *Lmx1a/b-Wnt1/Ctnnb* autoregulatory loop together with *Otx1/2* and *Foxa1/2*.

mDA neurogenesis

mDA neurogenesis takes place in the ventricular zone (VZ) of the mFP, when mDA progenitors divide to generate postmitotic cells




Fig. 2. Genetic networks controlling the development of the midbrain-hindbrain and mDA neurons in the mouse brain. Antero-posterior patterning (yellow area): The mutually repressive activities of *Otx2* in the midbrain (MB) and *Gbx2* in the hindbrain (HB) establish the midbrain-hindbrain boundary (MHB), where *Otx2* is inhibited in the hindbrain (HBi) and *Gbx2* in the midbrain (MBi). Midbrain floor plate (mFP) specification (blue area): LMX1B expression in the midbrain mFP directly regulates the expression of *Wnt1* and *Lmx1a*, which also regulate each other via CTNNB (*bCat*) or directly (LMX1A), forming an auto-regulatory loop (shown by red arrows). *Wnt1* regulates *Otx2* and *Lmx1a* via β -catenin, and *Lmx1a/b* regulate *Msx1* (*Wnt1*-*Lmx1a/b*-*Msx1* network). Ventral patterning (pink area): FOXA2 regulates *Shh*, which feeds back onto *Foxa2* via GLI (*Shh*-*Foxa2* network). FOXA2 also directly regulates *Lmx1a/b*, to coordinate the specification of mDA neurons. Lateral phenotypes (green area): Midbrain basal plate (mBP) markers (*Nkx2-2* and *Nkx6-1*) are inhibited in the mFP (FPI) by *Foxa2* and *Otx2* (*Nkx2-2*), and by *Msx1* (*Nkx6-1*). Neurogenesis (purple area): The expression of *Ngn2* is indirectly regulated by *Wnt5a*, *Foxa2* (via *Ferd3l* and *Hes1*), *Lmx1a/b* (via *Msx1*) and *Lxr alpha/beta* (*Nr1h3/Nr1h2*). *Wnt1/bCat* and *Otx2* regulate both *Ngn2* and *Mash1*. mDA neuroblasts and neurons (beige area): LMX1A directly regulates the expression of mDA postmitotic genes, such as *Nurr1* and *Pitx3*, which in turn regulate *Th*. These postmitotic genes are also regulated by *Foxa2*, *Ngn2*, *Wnt5a*, *Lxr alpha/beta*, *Wnt1/b-catenin* and *Otx2*. Solid lines indicate direct interactions as demonstrated by chromatin immunoprecipitation. All other interactions, whether direct or indirect, are shown by dashed lines. Arrowheads indicate activation and perpendicular lines denote inhibition.

which express the nuclear receptor *Nurr1*. These cells migrate through the intermediate zone (IZ) while they differentiate and become TH⁺ mDA neurons on reaching the mantle zone (MZ) (Fig. 3A). In rodents, mDA cells appear at E10.5, whereas, in humans, mDA neurogenesis begins between 5.0 and 6.0 weeks post conception (PC), peaks at weeks 6–8 (Almqvist et al., 1996;

Nelander et al., 2009) and ceases at weeks 10–11 (Freeman et al., 1991). mDA neurogenesis is controlled by two proneural genes of the basic-helix-loop-helix family, *Mash1* (mouse achaete-schute homolog 1) and *Ngn2* (*Neurog2*; neurogenin 2) (Fig. 2, purple area), expressed in the VZ of the mFP. *Ngn2* is required for mDA neurogenesis (Andersson et al., 2006a; Kele et al., 2006), whereas




Fig. 3. Gene expression in the mDA lineage. (A) Schematic representation of a section through the mFP at E11.5. The ventricular zone (VZ) contains radial glia cells (RG, blue) that undergo neurogenesis to generate postmitotic neuroblasts (yellow) that migrate radially through the intermediate zone (IZ), over the processes of the RG and differentiate into mDA neurons (red) in the marginal zone (MZ). As cells become mDA neurons, they migrate tangentially towards the substantia nigra pars compacta (SNc). Arrows indicate radial migration (RM) of neuroblasts and tangential migration (TM) of mDA neurons. (B) RG (blue) cells express morphogens, proneural and early transcription factors, some of which are also expressed in neuroblasts (Nb, yellow) and mDA neurons, defining the entire mDA lineage. ±, low levels of expression; +, expressed; A, mainly anterior midbrain; P, mainly posterior midbrain.

Table 1. Late transcription factor genes, such as *Nurr1*, *En1* and *Pitx3*, regulate the expression of multiple genes in mDA neurons

	TFs			mDA						NFs		Post		
	<i>Nurr1</i>	<i>En1</i>	<i>Pitx3</i>	<i>Aadcd/Ddc</i>	<i>Ahd2</i>	<i>TH</i>	<i>Vmat</i>	<i>Dat</i>	<i>Drd2</i>	<i>Bdnf</i>	<i>C-ret</i>	<i>Cck</i>	<i>Nts</i>	<i>Dlk1</i>
<i>Nurr1</i>		+	+	+	+	+	+	+	+	+	+			+
<i>En1</i>			+		+	+	+	+				+	+	
<i>Pitx3</i>	+	–			+	+	+	+	+	+		–	–	–

Note that *Pitx3* is highly expressed in the anterolateral mDA neurons, where it inhibits the expression of *en1* and posterior markers such as *cck*. +, positive regulation; –, negative regulation. TFs, transcription factors; NFs, neurotrophic factors; Post, posterior markers.

Mash1 is capable of partially compensating for the loss of *Ngn2* (Kele et al., 2006). These two proneural genes are directly or indirectly regulated by, and integrate information from, the Shh-Foxa2 and Lmx1a/b-Wnt1-Otx2 networks (Fig. 2, pink, blue and yellow areas), as well as nuclear receptors of the Liver X receptor family (*Lxra/Nr1h3* and *Lxrβ/Nr1h2*) (Sacchetti et al., 2009) and the morphogen *Wnt5a* (Andersson et al., 2008) in order to control mDA neurogenesis (Fig. 2, purple area).

Repression of *Shh*, but not *Foxa2*, by *Wnt1/Ctnnb* in the mFP is required for mDA neurogenesis (Andersson et al., 2013; Joksimovic et al., 2009b; Tang et al., 2009). *Foxa2* then, together with *Foxa1*, dose-dependently controls mDA neurogenesis (Ferri et al., 2007; Stott et al., 2013) in two ways, by directly regulating the basic helix-loop-helix gene *Ferd3l* (Fer3-like, also known as *Nato3*) and *Lmx1a* (via *Msx1*) (Metzakopian et al., 2012). Whereas *Ferd3l* regulates mDA neurogenesis by repressing *Hes1* (hairly and enhancer of Split 1) (Ono et al., 2010), a suppressor of pro-neural genes, *Lmx1a* increases the expression of *Ngn2* via *Msx1* (Andersson et al., 2006b) (Fig. 2, purple area).

However, CTNNB also regulates mDA neurogenesis by directly regulating the expression of *Lmx1a* and *Otx2* (Chung et al., 2009), and *Otx2* is required for mDA neurogenesis by controlling the expression of *Ngn2* and *Mash1* (Omodei et al., 2008; Prakash et al., 2006). Similarly, *Wnt1* is required for the expression of *Ngn2* and *Mash1* in the mFP and for mDA neurogenesis (Andersson et al., 2008). Another important factor for mDA neurogenesis is the morphogen *Wnt5a*, which is expressed in the VM at E9.5 and becomes restricted to the BP and the mFP by E11.5–13.5 (Fig. 1D,E). *Wnt5a* is expressed in mFP radial glia, neuroblasts and partially in posterior mDA neurons (Fig. 3B), where it inhibits *Foxa2*, *Ngn2* and *Nurr1* expression (Andersson et al., 2008) (Fig. 2, purple area). Accordingly, deletion of *Wnt5a* does not impair mDA neurogenesis, but rather increases the number of postmitotic NURR1⁺/TH⁺ cells (Andersson et al., 2008). Surprisingly, however, its deletion potentiates the neurogenesis defect in *Wnt1*^{−/−} mice, indicating that there is cooperation between both Wnts in mDA neurogenesis (Andersson et al., 2013).

LXRα and LXRβ are two additional regulators of mDA neurogenesis. These nuclear receptors are ligand-dependent transcription factors that form obligate heterodimers with RXR (retinoid X receptors). LXRs are required to maintain the expression levels of *Lmx1b*, *Wnt1* and *Ngn2* in the developing midbrain, and deletion of both *Lxr* receptors decreased mDA neurogenesis, whereas their overexpression increased it (Sacchetti et al., 2009) (Fig. 2, purple area). Moreover, activation of LXRs by the endogenous midbrain LXR ligand 24,25-epoxycholesterol has been shown to selectively and specifically promote mDA neurogenesis, in an LXR-dependent manner (Theofilopoulos et al., 2013). These results indicate that LXRs are both required and sufficient for mDA neurogenesis during development and that LXR ligands constitute a new class of selective and cell type-specific regulators of neurogenesis (Theofilopoulos et al., 2013).

Migration of postmitotic mDA neuroblasts and neurons

After neurogenesis, postmitotic cells migrate through the IZ towards their final destination in the MZ (Hanaway et al., 1971; Kawano et al., 1995). mDA cells first migrate radially along the vimentin⁺ radial glial processes (Shults et al., 1990) (Fig. 3A) and then tangentially, to reach their final position in the SN, VTA and RrF (Hanaway et al., 1971; Marchand and Poirier, 1983) (Fig. 1A). *Cxcr4* (C-X-C motif chemokine receptor type 4) can be detected in the IZ and MZ (Fig. 3B) and is required for radial migration and fiber outgrowth of mDA neurons between E11.5 and E14.5 (Bodea et al., 2014; Yang et al., 2013b). Its ligand, *Cxcl12* (C-X-C motif chemokine 12) is expressed in the meninges and is sufficient to promote the migration of mDA neurons (Yang et al., 2013b). Whereas pharmacological inhibition or deletion of *Cxcr4* does not affect the number of mDA neurons, it affects their migration, as some cells remain in the IZ and do not reach the MZ (Yang et al., 2013b). Tangential migration of mDA neurons is regulated by the neural L1 cell adhesion molecule (L1CAM) (Demyanenko et al., 2001; Ohyama et al., 1998) and RELN (reelin) (Kang et al., 2010; Nishikawa et al., 2003). Mice lacking *Reln* or the cytoplasmic adaptor protein *Dab1* (disabled 1) have fewer PSA-NCAM⁺ tangential fibers and fewer mDA neurons reaching the SNc, despite normal numbers of mDA neurons being generated (Kang et al., 2010). Moreover, the RELN receptors LRP8 (low density lipoprotein receptor-related protein 8, also known as ApoER2) and VLDLR (very low density lipoprotein receptor) are also required for the migration and final positioning of mDA neurons (Sharaf et al., 2013). Finally, *Ntn1* (netrin 1) regulates mDA neuron migration in the mFP (Livesey and Hunt, 1997), and deletion of the NTN1 receptor *Dcc* (deleted in colorectal cancer), results in not only dorsally displaced mDA neurons, but also in a loss of mDA neurons and aberrant innervation of nigrostriatal and mesocortical targets (Flores et al., 2005; Riedl and Salvesen, 2007; Xu et al., 2010). Thus, multiple pathways regulate mDA neuron migration – most notably CXCL12/CXCR4 to control radial migration, and RELN signaling to control tangential migration.

Differentiation and survival of mDA neurons

After neurogenesis, migratory postmitotic neuroblasts in the IZ differentiate into mDA neurons in the MZ. This process is regulated by some of the early factors described above, such as *Otx2*, *Lmx1a/b*, *Foxa1/2* and the homeobox genes *En1/2* (engrailed 1/2), which remain expressed in postmitotic mDA cells (Fig. 3B). Early factors in turn regulate the activity of late transcription factors, such as *Nurr1* and *Pitx3* (Fig. 2, beige, Fig. 3B), which control the progressive acquisition of appropriate neurotrophic factor and DA neurotransmitter phenotype (Table 1).

The morphogen WNT5A also promotes the differentiation of rodent and human midbrain progenitors into functional mDA neurons (Andersson et al., 2008; Parish et al., 2008; Ribeiro et al., 2012). *Wnt5a*^{−/−} mice show an excess of NURR1⁺/TH⁺ postmitotic DA neuroblasts but not mDA neurons, indicating a differentiation defect.

Wnt5a^{−/−} mice display typical convergent-extension morphogenic defects, resulting in a rostro-caudal shortening and medial-lateral widening of the mDA domain (Andersson et al., 2008). Deletion of *Wnt1* does not affect conversion-extension and, unlike *Wnt5a*, decreases the number of NURR1⁺ neuroblasts and TH⁺ mDA neurons (Andersson et al., 2013). However, simultaneous deletion of *Wnt5a* and *Wnt1* further enhances the *Wnt1*^{−/−} phenotype and reduces the number of NURR1⁺ and TH⁺ mDA neurons to a greater extent, indicating a cooperation between these two *Wnts* in mDA differentiation (Andersson et al., 2013) (Fig. 1D,E). *Wnt1* is also required for the survival of mDA neurons and the expression of *Pitx3* (Prakash et al., 2006) as well as LMX1A in the mFP (Andersson et al., 2013), where LMX1A/B directly regulates *Nurr1* and *Pitx3* (Chung et al., 2009). However, FOXA1/2 are required for the expression of *Nurr1*, *En1* and *Ddc* (dopa decarboxylase, also known as aromatic L-amino acid decarboxylase, *Aadc*) in mDA neuroblasts and neurons, as well as the expression of *Th* in mDA neurons (Ferri et al., 2007; Stott et al., 2013). Thus, the two morphogen-controlled gene networks in the mFP, *Wnt1-Lmx1a* and *Shh-Foxa2*, cooperatively regulate not only mDA specification and neurogenesis, but also differentiation and survival (Fig. 2, beige area).

Transcription factors that are expressed in postmitotic mDA neurons from E10–10.5 to adult stages and control the acquisition of a mature mDA phenotype include *Nurr1/Nr4a2* (Zetterström et al., 1996) and *Pitx3* (Maxwell et al., 2005) (Fig. 3B). *Nurr1* is required for mDA neuroblast survival and differentiation into TH⁺ mDA neurons (Zetterström et al., 1997). In *Nurr1*^{−/−} mice, mDA neuroblasts become PITX3⁺ but fail to survive and are gradually lost (Le et al., 1999; Saucedo-Cardenas et al., 1998). In agreement with this, NURR1 regulates the expression of several genes that define a mature mDA neuron, including *Th*, *Slc18a2/Vmat2* (solute carrier family-18 member-2/vesicular monoamine transporter-2), *Slc6a3/Dat* (solute carrier family-6 member-3/dopamine transporter), *Ddc/Aadc*, *Ret* (c-ret proto-oncogene), *Bdnf* (brain-derived neurotrophic factor) and *Cdkn1c* (cyclin-dependent kinase inhibitor 1C) (Gil et al., 2007; Jankovic et al., 2005; Joseph et al., 2003; Saucedo-Cardenas et al., 1998; Smits et al., 2003; Wallen et al., 2001; Volpicelli et al., 2007; Zetterström et al., 1997) (Fig. 3B; Table 1). *Pitx3* is one of the earliest markers of mDA neurons (Chung et al., 2005b; Jacobs et al., 2007; Nunes et al., 2003; Semina et al., 1997; Smidt et al., 1997). Unlike *Nurr1*, deletion of *Pitx3* does not change the number of VTA/A10 TH⁺ mDA neurons. However the number of SNc/A9 neurons progressively decreases in *Pitx3*^{−/−} mice and is dramatically reduced by birth, indicating that *Pitx3* is required for the survival of SNc/A9 mDA neurons (Hwang et al., 2003; Maxwell et al., 2005; Smidt et al., 2004; Smidt and Burbach, 2007; van den Munckhof et al., 2003; Yang et al., 2013b). One direct target of PITX3 is the *Aldh1a1* gene (aldehyde dehydrogenase-1a1, or *Ahd2*), which increases retinoic acid and upregulates *Th* and *Drd2* (dopamine receptor 2) but decreases *Dlk1* (delta-like 1 homolog) in anterior mDA cells (Jacobs et al., 2011). PITX3 also works independently of retinoic acid to upregulate *Vmat* and *DAT* and downregulate *Cck* (cholecystokinin) and *En1/2* (Jacobs et al., 2011; Veenvliet et al., 2013) (Table 1). Moreover, *Nurr1* and *Pitx3* regulate each other (Jacobs et al., 2009; Volpicelli et al., 2012) and are required for the maintenance of adult mDA neurons (Kadkhodaei et al., 2009; van den Munckhof et al., 2003). Interestingly, *Nurr1* also regulates *En1* (Sousa et al., 2007), which in turn regulates *Pitx3*, *Aldh1a1*, *Th*, *Slc18a2/Vmat2*, *Slc6a3/Dat*, *Cck* and *Nts* contributing to the proper induction of distinct mDA subsets (Veenvliet et al., 2013) (Table 1). Moreover, EN1/2 enhances the translation of mitochondrial complex I subunits and promotes the survival of adult mDA neurons in models of PD

in vivo (Alvarez-Fischer et al., 2011). In sum, NURR1, PITX3 and EN1/2 are crucial regulators of terminal differentiation, as well as survival and maintenance of mDA neurons (Fig. 2, beige area).

The survival of mDA neurons *in vitro* and in animal models of PD is regulated by several families of neurotrophic factors, including the transforming growth factor family (TGFβ2/3) (Poulsen et al., 1994; Roussa et al., 2009); members of the neurotrophin family, such as brain-derived neurotrophic factor (BDNF) (Frim et al., 1994; Hyman et al., 1991); glial cell-line-derived neurotrophic factor (GDNF) (Akerud et al., 2001; Arenas et al., 1995; Beck et al., 1995; Choi-Lundberg et al., 1997; Gash et al., 1996; Kordower et al., 2000; Lin et al., 1993; Rosenblad et al., 1998; Tomac et al., 1995); other members of the GDNF family, such as neurturin or persephin (Akerud et al., 1999, 2002; Horger et al., 1998; Rosenblad et al., 1999, 2000); and a novel family formed by mesencephalic astrocyte-derived neurotrophic factor (MANF) and conserved dopamine neurotrophic factor (CDNF or Armet1) (Lindholm et al., 2007; Petrova et al., 2003; Voutilainen et al., 2009).

Embryonic deletion of *Tgfb3* (Zhang et al., 2007), but not *Bdnf* or *Gdnf* (Baquet et al., 2005; Moore et al., 1996; Pichel et al., 1996; Sanchez et al., 1996), reduced the numbers of mDA neurons. However, conditional deletion of *Gdnf* in adult mice (*Gdnf*^{fl}/*Cre-ERTM*) causes mDA neuron loss (Pascual et al., 2008), indicating that GDNF is subsequently required to maintain the survival of mDA neurons. Interestingly, members of the TGFβ family are required for GDNF to exert its effects (Kriegstein et al., 1998), and the expression of the GDNF receptor *c-ret* (Trupp et al., 1996) is maintained by *Nurr1* (Decressac et al., 2012). Moreover, GDNF has been suggested to regulate *Bdnf* expression via a *Gdnf-Pitx3-Bdnf* trophic loop (Peng et al., 2011). Thus, multiple lines of evidence indicate that networks formed by morphogens, transcription factors and neurotrophic factors promote the differentiation and survival of mDA neurons.

Generating human mDA neurons *in vitro*

Our ability to recreate human mDA neurons *in vitro* has built in large part on the growing knowledge of how these cells develop *in vivo* and has opened up unprecedented opportunities in disease modeling, drug discovery and cell replacement therapies for PD. Multiple candidate cell sources are now available to generate DA neurons that are potentially suitable for therapeutic applications (Fig. 4). These include endogenous fetal NS/PCs, PSCs and adult somatic cells, which can be used for reprogramming (Fig. 4A–D). However, not all protocols are equally efficient. Notably, NS/PCs expanded with mitogens as monolayers (Sanchez-Pernaute et al., 2001) or neurospheres (Maciaczyk et al., 2008; Riaz et al., 2002; Ribeiro et al., 2012), or when immortalized (Castelo-Branco et al., 2006; Courtois et al., 2010; Ramos-Moreno et al., 2012; Wagner et al., 1999), have shown variable numbers and quality of DA neurons (Fig. 5A–E), probably due to heterogeneity and/or late developmental stage of the cells and the protocols used. More recently, long-term-neuroepithelial stem (lt-NES) cells have emerged as a more homogeneous early stage population that can be derived from either human fetal hindbrain tissue (Tailor et al., 2013) or PSCs, which can be differentiated into TH⁺ neurons (Falk et al., 2012; Koch et al., 2009) (Fig. 5F). However, it remains to be determined whether these cells could generate correctly specified mDA neurons with more advanced differentiation protocols. In this section, we will first focus on human PSCs, which can be correctly specified into mDA neurons that are functional *in vivo*, and are thus the closest to a potential clinical application; and second, on somatic cell




Fig. 4. Regenerative medicine-based strategies for the treatment of Parkinson's disease. (A) Human fetal ventral midbrain (VM) tissue has been the classical source of tissue for transplantation and has provided proof of principle for cell replacement therapy in Parkinson's disease (PD). (B,C) Midbrain dopaminergic neurons have also been generated from human PSCs, derived either from blastocysts (ESCs; B) or by reprogramming of fibroblasts (iPSCs; C). Protocols involve following the developmental steps to first generate ectoderm, neural plate (NP) and neuroepithelial cells (NEP), followed by midbrain floor plate (mFP), midbrain dopaminergic (mDA) progenitors (mDP), mDA postmitotic neuroblasts (mDNb) and mDA neurons. (D) An alternative way to create mDA neurons is by direct reprogramming of fibroblasts into induced mDA neurons. (E) mDA neurons and iDA cells can be used for transplantation. (F) Direct reprogramming could also be performed *in vivo*, to generate iDA neurons *in situ*, from host cells in the adult brain, without the need for cell transplantation. (G) mDA neurons derived from PD patients or with introduced PD mutations can be compared with controls or corrected mutations and used for disease modeling and drug discovery.

reprogramming, a novel and promising strategy to generate DA neurons.

Directed differentiation of PSCs into mDA neurons

Human PSCs (hPSCs), whether derived from the inner cell mass of an embryo at the blastocyst stage (embryonic stem cells, ESCs) (Thomson et al., 1998), or generated via reprogramming of differentiated somatic cells (induced pluripotent stem cells, iPSCs) (Takahashi et al., 2007), are an attractive cell source for regenerative medicine, given their capacity to self-renew and to generate all the cell types in an organism. Numerous protocols describing the differentiation of mDA neurons from PSCs have been developed during the last decade. Initial approaches to generate human DA neurons were based on adaptations of mouse NS/PC and ESC protocols, which relied on the generation of embryoid bodies, the use of stromal cells or astrocytes as feeders, and the activation of a few key signaling pathways (SHH, FGF8, NURR1) to recapitulate some aspects of mouse embryonic development (Kawasaki et al., 2000; Kim et al., 2002; Lee et al., 2000; Wagner et al., 1999). Early human ESC differentiation protocols produced high numbers of TH⁺ neurons (Park et al., 2005; Perrier et al., 2004; Roy et al., 2006; Zeng et al., 2004), but none of them generated cells co-expressing two transcription factors required for proper mDA neuron specification, FOXA2 and LMX1A. Early protocols resulted in incorrectly specified TH⁺ cells (Perrier et al., 2004) that, although

capable of releasing dopamine, survived poorly after transplantation (Park et al., 2005), and could overgrow and generate undesirable progeny (Roy et al., 2006; Zeng et al., 2004).

One of the first protocols to induce correctly specified mDA neurons from human ESCs (hESCs) was based on the forced expression of *LMX1A* in hESCs treated with SHH and FGF8 (Friling et al., 2009). The resulting cultures contained 50% TH⁺ neurons, most of which co-expressed mDA markers, such as LMX1B, NURR1, PITX3 and DAT (Fig. 5G). Moreover, very few serotonin or motor neurons were detected in the cultures, suggesting selective mDA specification. A similar protocol produced human mDA neurons that released dopamine, exhibited appropriate electrophysiological properties and survived intracerebral transplantation for up to 5 months (Sanchez-Danes et al., 2012a). However, the *in vivo* functionality of human *LMX1A*-overexpressing cells in animal models of PD was not examined.

A more rigorous temporal implementation and recapitulation of morphogenic signals important for mDA neuron development improved the differentiation protocols. The use of dual SMAD inhibitors at the beginning of the differentiation protocol, to inhibit BMP, nodal, activin and TGFβ signaling, improved neural induction and eliminated the need for feeder layers (Chambers et al., 2009). However, this protocol relied on patterning with SHH and FGF8 and did not result in correctly specified mDA neurons (Fig. 5H). Subsequently, it was found that administration of




Fig. 5. Protocols for the differentiation of human NS/PCs (A-E) and PSCs (F-M) into mDA neurons. Human fetal VM tissue has been used for the expansion and differentiation of mDA progenitors/stem cells into TH⁺ cells (yellow) or correctly specified mDA neurons (red). These cells have been grown as monolayers (A), neurospheres (B-D) or immortalized cell lines (E). Human PSCs (hPSCs) derived from blastocysts (ESCs) or reprogrammed fibroblasts (iPSCs) have been used to generate stable long-term neuroepithelial stem (It-NES) cells (F), embryoid bodies (EB, G), or for direct differentiation into mDA neurons (H-M). References: A, Sanchez-Pernaute et al. (2001); B, Riaz et al. (2002); C, Maciaczyk et al. (2008); D, Ribeiro et al. (2012); E, Courtois et al. (2010); F, Falk et al. (2012); Koch et al. (2009); G, Friling et al. (2009); H, Chambers et al. (2009); I, Kriks et al. (2011); J, Kirkeby et al. (2012); K, Denham et al. (2012); L, Xi et al. (2012); M, Doi et al. (2014). Small molecules, such as GSK3 β inhibitors (GSK3i), have allowed mFP induction and mDA specification. SMAD inhibitors (LDN, SB, A83-01) have substituted noggin (NOG). Shh has been substituted by the smoothened agonist (SAG) and/or purmorphamine (Pur). AA, ascorbic acid; DAPT, γ -secretase inhibitor; dbcAMP, dibutyryl cyclic adenosine monophosphate; FK, forskolin. Green lightning symbols in E and G indicate overexpression of the indicated factors. * Circled asterisk indicates cells that have shown functionality in animal models of PD.

high levels of SHH during neural induction was crucial for FP specification (Fasano et al., 2010). However, correct midbrain specification was not achieved until WNT/ β -catenin signaling, an essential pathway in mDA neuron development (Andersson et al., 2013; Castelo-Branco et al., 2004, 2003; Chung et al., 2009; Joksimovic et al., 2009b; Prakash et al., 2006; Tang et al., 2010; Yang et al., 2013a), was implemented. Indeed, addition of GSK3 β inhibitors allowed for the generation of correctly specified hPSC-derived mDA neurons in a reliable and efficient manner. This was first clearly demonstrated by the Studer group (Kriks et al., 2011), who produced cultures with 80% FOXA2⁺ cells and 75% TH⁺ cells (Fig. 5I). Further characterization of these cultures revealed abundant expression of genes involved in mDA neuron development and high levels of co-localization of LMX1A and FOXA2 in DA progenitors and neurons, indicating correct mDA specification. These cells exhibited biochemical and electrophysiological properties of mature mDA neurons, and, when transplanted in rodent models of PD, they survived, retained marker expression, did not form overgrowths and induced functional recovery in a battery of drug-induced and spontaneous motor-behavioral tests. Subsequently, the Parmar group used a similar protocol, but involving the formation of embryoid bodies (Kirkeby et al., 2012). This also led to correctly specified and functional mDA cells capable of long-term survival without overgrowth formation, which innervated target structures and improved both drug-induced and spontaneous motor behavior in a rat unilateral 6-OHDA model of PD, similar to fetal human midbrain tissue (Grealish et al., 2014). GSK3 β inhibitors have been also successfully used in other protocols to produce correctly specified mDA neurons (Denham et al., 2012; Xi et al., 2012) (Fig. 5K,L). These protocols varied somewhat in the doses and the starting day of GSK3 β inhibitor treatment, with day 3 mimicking closer midbrain development. Finally, a more recent study used laminin 511-E8 to promote adhesion of hPS-derived cells during mFP induction, followed by differentiation as floating spheres (Fig. 5M) (Doi et al., 2014). These protocols lead to correctly specified mDA neurons that survived transplantation and improved drug-induced circling behavior.

These recent reports emphasize the importance of implementing development-based protocols to recapitulate the *in vivo* exposure to morphogens such as WNT1 and SHH. In this context, it should be noted that GSK3 β inhibitors have off-target effects (Bain et al., 2007) and that GSK3 β regulates pathways other than WNT/ β -catenin (Hur and Zhou, 2010). Moreover, activating WNT/ β -catenin signaling in dopaminergic cells does not always lead to mDA differentiation, as found in the case of WNT3A (Andersson et al., 2013; Castelo-Branco et al., 2003). Future experiments should thus focus on examining whether other pathways are activated and the extent to which these are required for the observed effects. Furthermore, the need for other factors in WNT/ β -catenin-activated cultures should be reassessed. For instance, in the absence of GSK3 β inhibitors, a period of FGF/ERK signaling blockade followed by FGF8 treatment upregulated *Wnt1* and promoted mDA differentiation of ESCs (Jaeger et al., 2011). However, in the presence of GSK3 β inhibitors, FGF8 was not required for mDA differentiation of ESCs (Kirkeby et al., 2012). In sum, understanding the precise effect of and requirement for different signaling molecules is essential in order to further refine current protocols, to develop cell replacement therapies and to selectively generate mDA neurons of the SNc/A9 subtype (Box 2), the cells that improve functional outcomes in animal models of PD (Grealish et al., 2010).

Direct reprogramming of somatic cells into mDA neurons

The discovery that mature somatic cells such as fibroblasts can be reprogrammed into iPSCs (Takahashi and Yamanaka, 2006) or other somatic cell types (Davis et al., 1987) by forced expression of transcription factors has revolutionized regenerative medicine, as it indicates that we might be able to generate any cell type from a mature somatic cell. Direct reprogramming relies on our capacity to directly (by forced expression) or indirectly (i.e. via microRNAs and small molecules) regulate the activity of lineage-specific transcription factors that reassign cell fate (Ladewig et al., 2013). To date, numerous somatic cell types have been generated via direct reprogramming, including induced DA (iDA) neurons that have been used for transplantation (Caiazzo et al., 2011; Dell'Anno et al., 2014; Kim et al., 2011; Liu et al., 2012b; Pfisterer et al., 2011; Torper et al., 2013) (Fig. 4D,E).

In vitro, induced neurons (iNs) have been obtained by forced expression of pan-neuronal factors in cells derived from the three germinal layers of the embryo (Fig. 6A). The most common factors used to reprogram fibroblasts (Vierbuchen et al., 2010), hepatocytes (Marro et al., 2011) or astrocytes (Torper et al., 2013) into iNs are *Brn1*, *Ascl1* and *Myt1l* (*BAM*). By contrast, the reprogramming of iDA cells (Fig. 6B) was achieved using midbrain-specific factors, such as *Lmx1a*, *Ascl1* and *Nurr1* (*LAN*) alone (Caiazzo et al., 2011) or together with additional factors, such as *Foxa2*, *En1* and *Pitx3* (Kim et al., 2011). In both cases, the resulting iDA cells showed expression profiles resembling more closely those of mDA neurons than of fibroblasts. iDA cells expressed endogenous *Lmx1a* (Caiazzo et al., 2011) or endogenous *Nurr1* and *Pitx3* as well as *eGFP* from the endogenous *Pitx3* locus (Kim et al., 2011). Furthermore, the rodent-

Box 2. DA neuron subpopulations

mDA neurons are traditionally classified by their anatomical position, projection field, function and marker expression. SNc/A9 DA neurons primarily express *Aldh1a1* and *Girk2/KCNJ6* (G protein-regulated inward rectifier K⁺ channel subfamily-J member-6), whereas VTA/A10 neurons predominantly express the calcium-binding proteins *Calb1*, *Calb2* (calbindin 1 and 2) and *Cck* (cholecystokinin) (Veenvliet et al., 2013).

Recent studies have shown that *Otx2* is predominantly expressed in VTA/A10 neurons in the developing and adult brain (Chung et al., 2005a; Di Salvio et al., 2010a,b) and is selectively required for the specification (Di Salvio et al., 2010a) and neurogenesis (Di Giovannantonio et al., 2013) of VTA/A10 neurons. Similarly, *Wnt1* hypomorphic mice (swaying, *Wnt1*^{SW/SW}) exhibit a complete loss of VTA, but not SNc mDA neurons, a phenotype transiently phenocopied by *Fgf8* conditional knockout (*En1*^{Cre}) mice, at E12.5 (Ellisor et al., 2012). On the contrary, conditional deletion of *Foxa1* and *Foxa2* (*DAT*^{Cre/+}; *Foxa1/2*) showed a greater loss of *Girk2* and SNc/A9 than *Calb1* and VTA/A10 neurons (Stott et al., 2013). Similarly, deletion of *Sox6*, a factor predominantly expressed in SNc/A9 neurons, reduced the number of TH⁺/Aldh1a1⁺ SNc/A9 neurons, while increasing that of TH⁺/Cb⁺ VTA/A10 neurons, indicating that *Sox6* is required for the specification of A9 neurons (Panman et al., 2014). Thus, whereas *Otx2* and *Wnt1* are predominantly required for the specification of VTA/A10 neurons, *Foxa1/2* and *Sox6* are mainly necessary for the specification of SNc/A9 neurons. Combined, these results suggest that the balance between the *Otx2*-*Wnt1*-*Lmx1a/b* and the *Shh*-*Foxa1/2* pathways (Fig. 2) control mDA neuron subtype specification.

However, our knowledge of the molecular differences between these cells is still limited, and it is possible that additional genes are ultimately responsible for subtype identity. Interestingly, five molecularly distinct mDA neuron subtypes in mice have been suggested very recently (Poulin et al., 2014). Studies examining unbiased global gene expression in single human mDA neurons are required to confirm and identify novel, molecularly defined mDA neuron subtypes.




Fig. 6. Direct reprogramming of somatic cells into induced neurons and dopamine neurons. Cells from different species (mouse, blue arrows; human, red arrows; both, green arrows) and germ layers (endoderm, blue area; mesoderm, green area; ectoderm, yellow area) have been reprogrammed into neurons. (A) Schematic representation of the protocols used to obtain induced neurons (iNs) *in vitro*, from hepatocytes, fibroblasts, hematopoietic cells, pericytes and astrocytes. Proteins and small molecules are in parentheses. Factor combinations: *BAM* (*Brn1*, *Ascl1* and *Myt1l*); *LAN* (*Lmx1a*, *Ascl1* and *Nurr1*). References: a, Heins et al. (2002); b, Berninger et al. (2007); Heinrich et al. (2010, 2011); c, Karow et al. (2012); d, Vierbuchen et al. (2010); e, Marro et al. (2011); f, Pfisterer et al. (2011); g, Pang et al. (2011); h, Qiang et al. (2011); i, Yoo et al. (2011); j, Ambasudhan et al. (2011); k, Ladewig et al. (2012); l, Xue et al. (2013); m, Torper et al. (2013); n, Guo et al. (2014); o, Castañón et al. (2014). (B) Induced dopamine neurons (iDAs) have been generated *in vitro* from fibroblasts and astrocytes by different protocols. References: a, Caiazzo et al. (2011); b, Kim et al. (2011); c, Addis et al. (2011); d, Pfisterer et al. (2011); e, Torper et al. (2013); f, Liu et al. (2012b). (C) Induced neurons produced *in vivo* by reprogramming of endogenous mouse brain cells, such as astrocytes and NG2⁺ cells in the cerebral cortex (CTX), spinal cord (SC) or striatum (STR) *in situ*. Whereas cells with glutamatergic (Glu) or GABAergic traits (GABA) have been observed, iDA neurons have not yet been obtained from adult brain cells *in vivo*. References: a, Grande et al. (2013); b, Torper et al. (2013); c, Niu et al. (2013); d, Su et al. (2014); e, Guo et al. (2014); f, Heinrich et al. (2014). AD, Alzheimer's disease transgenic model; CHIR, GSK3b inhibitor; NOG, noggin; SB, Smad inhibitor; VPA, valproic acid.

derived cells exhibited mature DA neuronal properties as defined electrophysiologically and through dopamine release. Lastly, these two studies showed integration of murine-derived iDA cells into the mouse brain. The iDA neurons produced by Kim and colleagues were able to partially alleviate motor deficits in a mouse model of PD, but required tenfold more cells than fetal DA tissue grafts, indicating that their level of functionality is low (Kim et al., 2011). A slight variation of this protocol, using *Lmx1b* instead of *Lmx1a*, also reprogrammed primary mouse postnatal cortex astrocytes into functional iDA cells, although these have not been tested *in vivo* (Addis et al., 2011). Notably, the fact that somatic cell types derived from different germ layers, such as fibroblasts and astrocytes, can be reprogrammed into iDA cells by a similar combination of factors highlights the inherent robustness of such factors in the reprogramming process.

In an alternative strategy, a pan-neuronal identity was first induced with *BAM*, before further mDA neuron factors were added, including *Lmx1a* and *Foxa2* alone (Pfisterer et al., 2011) or in combination with *Lmx1b* and *Otx2* (Torper et al., 2013). These cells successfully engrafted in the striatum of a 6-OHDA rat model of PD, but very few cells survived after 6 weeks (Pfisterer et al., 2011), indicating that they do not behave like human fetal or hESC-derived mDA neurons. In another study, *Ascl1*, *Nurr1*, *Pitx3* and two additional factors, *Sox2* and *Ngn2*, but not *Lmx1a*, were used (Liu et al., 2012b), although, again, the resulting iDA cells engrafted in the striatum of 6-OHDA lesioned rats but survived poorly and did not exhibit a neuronal morphology.

More recently, the Broccoli group (Dell'Anno et al., 2014) demonstrated pan-DA marker expression, functional integration *in vivo* without tumor formation or overgrowths, and partial reduction of motor deficits in an *in vivo* model of PD by using mouse iDA cells reprogrammed with LAN. Expression of DREADDs (designer receptors exclusively activated by designer drugs) in iDA cells and treatment with the corresponding ligand further improved firing activity, dopamine release and behavioral recovery in a model of PD. These results represent an important milestone in the field as the efficiency of iDA cells was comparable to that of embryonic mDA neuron grafts. In the future, it will be important to perform similar studies with human iDA cells and examine their *in vivo* long-term expression of midbrain-specific markers.

Direct *in vivo* reprogramming of *in situ* adult mouse brain cells into neurons has become a reality in recent years (Fig. 4F), although iDA cells have not yet been obtained *in vivo*. Neurons have been reprogrammed from other types of neurons (De la Rossa et al., 2013; Rouaux and Arlotta, 2013), unidentified non-neuronal cells (Grande et al., 2013) (Fig. 6Ca), astrocytes (Guo et al., 2014; Niu et al., 2013; Su et al., 2014; Torper et al., 2013) (Fig. 6Cb–e), and NG2⁺ cells (Guo et al., 2014; Heinrich et al., 2014) (Fig. 6Ce,f) have been reprogrammed into neurons *in vivo*. These neurons have shown mature electrophysiological properties, but their neuronal phenotypes are often incomplete and their numbers are low. Further developments are thus necessary to develop this method for cell replacement therapy for PD. Notably, injury promoted (Grande et al., 2013; Guo et al., 2014) or was required (Heinrich et al., 2014) for neuronal reprogramming *in vivo*, indicating that this strategy is particularly well suited for neural repair. Indeed, the reprogramming of glial cells into neurons would allow neurons lost by disease to be replaced, while reducing the excess of reactive glia, and regaining balance between glia and neurons in neurodegenerative diseases.

The induction of iDA cells: a regulatory logic?

The various combinations of reprogramming factors used to generate iDA neurons *in vitro* (Fig. 6B) all combine *Ascl1* with

additional midbrain- and DA neuron-specific transcription factor genes. As *Ascl1* alone is sufficient to convert mouse fibroblasts into iN cells (Chanda et al., 2014; Vierbuchen et al., 2010), but is not required for mDA neuron development (Kele et al., 2006), *Ascl1* is likely to play a generic neurogenic or neuronal reprogramming role and has been proposed to act as a pioneer factor (Wapinski et al., 2013). Another gene widely used for the induction of mDA fate is *Lmx1a*, a known fate determinant required for mDA neuron development (Andersson et al., 2006b; Deng et al., 2011), which is essential for mDA neuron programming and a core component in direct iDA reprogramming. Other midbrain transcription factor genes, such as *Nurr1*, *Foxa2* and *Pitx3*, appear dispensable as single genes in some of the protocols, but in combination with *Ascl1*, and at least one other mDA transcription factor, contribute to improve iDA reprogramming. Thus, currently available data suggest a model in which the acquisition of an iDA phenotype requires the combination of the pioneer factor *Ascl1*, *Lmx1a* as a core iDA reprogramming factor, and at least one or more mDA neuron transcription factor, as helpers in iDA reprogramming. Combined, these results indicate that iDA reprogramming follows basic developmental principles and emphasizes the importance of understanding the mechanism of action of developmental factors in the context of reprogramming. In the future, it will be important to characterize the transcriptional networks and phenotype of iDA cells in order to determine whether a mature mDA-like iDA cell can be generated, whether different protocols lead to similar or distinct iDA cells and whether different cells correspond to separate routes and/or stages of reprogramming.

Conclusions, perspectives and future directions

Our knowledge of the developmental mechanisms that regulate mDA neuron development, as well as the tools currently available for generating mDA neurons (cells, factors and protocols), have grown exponentially in the last few years. These developments have generated optimism in the regenerative medicine field with regard to the future development of cell replacement therapy and drug discovery for PD. However, issues important for mDA neuron development and phenotype stability, such as genetic and epigenetic regulatory mechanisms or the strength of signaling, are still poorly understood.

Reprogrammed iDA cells for cell transplantation

As discussed above, direct reprogramming is currently emerging as a possible alternative to stem cell-derived mDA neurons for cell replacement therapy. The advantages of such a method would be that it could avoid the generation of proliferative immature cells, reducing the risk of tumor/outgrowth formation, and autologous cells would not require immunosuppression. However, it remains to be determined whether the phenotype and functionality of directly reprogrammed human iDA cells is the same as human mDA neurons derived from other sources, and whether transplanted human iDA cells are sufficiently stable and safe to be used for long-term correction of functional and behavioral deficits in models of PD. Progress in the generation of iDA cells will thus require: (1) A better understanding and ability to optimize the iDA reprogramming mechanisms, potentially by exploiting novel microRNAs or small molecules; (2) a detailed characterization of the iDA phenotypes generated by distinct reprogramming factor combinations, and of phenotype stability compared with endogenous DA cells; (3) determining the safety of the method with regard to insertional mutagenesis, partial reprogramming, proliferation and host inflammatory/immune response; (4) for *in vivo* iDA reprogramming, the development of

cell type-specific efficient reprogramming methods to selectively target the desired cell type whilst avoiding possible damage to other cells. So far, no iDA cells have been produced from endogenous adult brain cells *in vivo*, and selective targeting has been achieved by using Cre-recombinase or tetracycline transactivator (tTA) driver mouse lines. Viruses or carriers capable of selectively, efficiently and safely targeting specific cell types will be necessary in the future.

Towards cell replacement therapies for PD with PSCs

Recent protocols for generating mDA neurons from hPSCs offer the possibility of generating an unlimited number of safe and functional cells *in vivo* (Kriks et al., 2011) that survive for up to 6 months. In addition, they are capable of innervating distant target structures (Grealish et al., 2014) and modulating the glutamatergic input to striatal medium spiny neurons (Steinbeck et al., 2015). This has been made possible because of an improved understanding of mDA neuron development and a focus on studying human cells, overcoming species differences and allowing the preclinical development of stem cell-based cell replacement therapy for PD. Future challenges include improving our understanding of mDA neuron subtype specification and developing more effective protocols to generate human SNc/A9 mDA neurons. Strategies to improve protocols might involve cell sorting (Box 3), the incorporation of novel developmental factors to current differentiation protocols, as well as achieving the right signaling level or balance between different factors and pathways (Box 2; Fig. 2). Shorter protocols, for example starting from hPSC-derived mDA progenitors, would also facilitate the development of clinical applications by saving time and costs. All these protocols will need to be upscalable, use defined human components and be thoroughly tested in order to be good manufacturing practice (GMP) compliant and thus useful for cell replacement therapy in the clinic. Moreover, the functionality of GMP-produced hPSC-derived mDA neurons should also be examined in animal models of PD. For use in replacement therapy, cells must meet a number of criteria, including the ability to (1) not only survive transplantation, but integrate without excessive growth; (2) acquire a stable mature phenotype *in vivo* with the loss of immature markers in long-term surviving grafts; (3)

re-innervate the host striatum, but no other targets; (4) release dopamine and exhibit appropriate electrophysiological properties; (5) induce functional recovery in sensorimotor behavioral tests relevant to PD; and (6) attain an homogeneous population of highly efficient SNc/A9 cells in order to reduce the number of cells required for transplantation. Finally, transplantation in primates might be useful in order to prepare clinical trials and ascertain the degree of fiber outgrowth and functional capacity of the cells, as well as issues of immunogenicity in the case of allogeneic or autologous iPSC/iN work.

The challenges facing cell replacement therapy in PD are great because new therapies need to be competitive against existing therapies, such as L-DOPA or DBS. The experience from successful open label trials using fetal hVM tissue suggests that cell replacement can be a competitive therapy. However, in order to further develop this strategy, new double-blind fetal tissue clinical trials with improved structure are needed (Evans et al., 2012). Future trials will also probably involve the use of hPSCs, as they are more amenable and upscalable sources of mDA neurons. hESCs are currently considered safer than iPSCs, as they do not require genetic modification. However, iPSCs can be generated with safer non-integrative methods, such as RNA or protein transduction or small molecules (Hargus et al., 2010; Kiskinis and Eggan, 2010; Sundberg et al., 2013). The advantage of iPSCs is that they can be derived from readily accessible autologous somatic cells, which is ethically less controversial. Moreover, PD-iPSCs would not require immunosuppression, but they might carry genetic or environmental damage, predisposing them to the development of PD. Avoiding this problem would involve correction of the cells or the use of immunosuppression with hESCs or hiPSCs derived from healthy individuals. Either way, the creation of hPSC banks covering the main human leukocyte antigens (HLAs) might allow treatment of multiple patients.

Reprogrammed cells as tools for disease modeling and drug discovery

PD iPSC-derived mDA, but not PD iDA cells, have been so far used for PD modeling. The main advantage of human PD iPSC-derived mDA cells compared with non-reprogramming strategies is that

Box 3. Selection of mDA cells for transplantation

In many cases, differentiation and reprogramming protocols generate heterogeneous populations of cells. Fluorescence-activated cell sorting (FACS) can be used both to remove undesired cell types and to enrich for mDA neurons or subtypes thereof. This approach has been used to select for neural fate, by using markers such as the glycoprotein CD133 (prominin 1, PROM1) and NCAM1 (neural cell adhesion molecule 1, or CD56) (Pruszek et al., 2007). For transplantation studies (Fig. 4E), committed, but not fully differentiated mDA rodent cells (Jönsson et al., 2009; Villaescusa and Arenas, 2010) at a NURR1⁺ neuroblast stage (Ganat et al., 2012), have been found to perform best.

More recently, NCAM⁺CD29^{low} (CD29 for integrin beta 1 or ITGB1) cells were sorted from a population of human PSCs differentiated with the midbrain floor plate protocol (Sundberg et al., 2013) to remove non-neural tumorigenic cells and enrich for FOXA2, LMX1A and TH⁺ neurons. The transplantation of these cells led to improved behavioral recovery in an animal model of PD (Sundberg et al., 2013). Similarly, human iPSCs sorted with CORIN and expressing the mDA markers FOXA2 and LMX1A survived grafting in 6-OHDA lesioned rats and induced behavioral recovery without tumor formation (Doi et al., 2014). However, sorting protocols that enrich for SNc/A9 cells have yet to be developed, and it is also important to eliminate cell types such as serotonergic cells that might cause side graft-induced dyskinesias (Carlsson et al., 2009, 2007; Politis et al., 2010).

Box 4. Generation of mDA cells for *in vitro* PD modeling

With the advent of reprogramming technologies, PD-specific iDA cells and iPSC-derived DA neurons have become very attractive options for PD modeling (Fig. 4G). Thus far, studies have focused on PD-iPSCs carrying *LRKK2* mutations (Cooper et al., 2012; Liu et al., 2012a; Nguyen et al., 2011; Reinhardt et al., 2013; Sanchez-Danes et al., 2012b; Sanders et al., 2014), *SNCA* triplication (Byers et al., 2011; Devine et al., 2011), *SNCA*^{A53T} mutation (Ryan et al., 2013; Soldner et al., 2011), *PINK* mutations (Cooper et al., 2012; Seibler et al., 2011) or *GBA1* heterozygosity (Mazzulli et al., 2011; Schöndorf et al., 2014). Most of these studies relied on protocols with suboptimal WNT/ β -catenin activation, which do not give rise to correctly specified mDA neurons. However, those studies using sufficient WNT/ β -catenin activation led to cell preparations with variable percentages of mDA neurons, ranging from 20% (Schöndorf et al., 2014) to 70% (Ryan et al., 2013).

As alterations in PD are cell-type specific and context dependent, it is necessary to further improve current mDA differentiation protocols for PD-iPSCs. Key considerations include the generation of control and PD-iPSC cells with identical genetic backgrounds (Hockemeyer et al., 2009; Maetzel et al., 2014; Wang et al., 2013; Zou et al., 2009), improving yield of correctly specified and functional SNc/A9 neurons, reducing the culture time by starting from stable intermediates (e.g. mDA progenitors) and developing high content assays, in which the cells of interest and their phenotypes are examined at a single-cell level at an appropriate spatial and temporal resolution (Jain and Heutink, 2010; Xia and Wong, 2012).

modeling is performed in human cells directly derived from PD patients (Box 4). This allows the study of features related to the genetic background of the patients, such as mutations, haplotypes or polymorphisms associated with the development of certain types and features of PD. Another advantage of reprogrammed cells is that, compared with postmortem samples, they can capture early stages of the disease, which might be crucial for the development of therapies aimed at preventing neurodegeneration. Reprogrammed cells can be used to generate other cell types affected in PD or even create neural organoids (Kadoshima et al., 2013; Lancaster et al., 2013), which have opened up the possibility of modeling features related to the anatomical or functional organization of cells in a tissue. So far, correctly specified PD-iPS-derived mDA neurons have been successfully used to model oxidative and nitrosative stress (Ryan et al., 2013), as well as autophagic defects in PD (Schöndorf et al., 2014). PD-iPSCs are thus considered the cell type of choice for high-throughput screening (HTPS) and drug development.

Gene editing technologies, such as zinc-finger nucleases, TALENs or the *CRISPR/Cas9* system, are currently being used to correct or introduce PD mutations and control for the genetic background of PD-iPSCs (Chung et al., 2013; Liu et al., 2012a; Reinhardt et al., 2013; Ryan et al., 2013; Sanders et al., 2014; Schöndorf et al., 2014; Soldner et al., 2011). These methods can be used to introduce/correct multiple mutations and examine epistatic interactions between PD genes, allowing more complete iPSC models in which several features of PD are simultaneously examined. In sum, multiple developments in this fascinating area of research are likely to improve *in vitro* modeling and drug discovery for PD, which, in turn, should contribute to novel therapeutic interventions.

Acknowledgements

We would like to thank Roger Barker and members of the Arenas lab for critical reading of the manuscript.

Competing interests

The authors declare no competing or financial interests.

Funding

This work was supported by grants from the Swedish Foundation for Strategic Research (CEDB and SRL Program), the Swedish Research Council [VR2008:2811 and 3287, VR2011:3116 and DBRM], Karolinska Institutet (SFO, Thematic Center in Stem Cells and Regenerative Medicine), the European Commission [NeuroStemCellRepair: HEALTH-F4-2013-602278 and DDPDGENES: HEALTH-2011-278871] and the Czech Ministry of Education and European Regional Development Fund [KI-MU; CZ.1.07/2.3.00/20.0180].

References

- Addis, R. C., Hsu, F.-C., Wright, R. L., Dichter, M. A., Coulter, D. A. and Gearhart, J. D. (2011). Efficient conversion of astrocytes to functional midbrain dopaminergic neurons using a single polycistronic vector. *PLoS ONE* **6**, e28719.
- Agid, Y., Taquet, H., Cesselin, F., Epelbaum, J. and Javoy-Agid, F. (1986). Neuropeptides and Parkinson's disease. *Prog. Brain Res.* **66**, 107–116.
- Akerud, P., Alberch, J., Eketjäll, S., Wagner, J. and Arenas, E. (1999). Differential effects of glial cell line-derived neurotrophic factor and neurturin on developing and adult substantia nigra dopaminergic neurons. *J. Neurochem.* **73**, 70–78.
- Akerud, P., Canals, J. M., Snyder, E. Y. and Arenas, E. (2001). Neuroprotection through delivery of glial cell line-derived neurotrophic factor by neural stem cells in a mouse model of Parkinson's disease. *J. Neurosci.* **21**, 8108–8118.
- Akerud, P., Holm, P. C., Castelo-Branco, G., Sousa, K., Rodriguez, F. J. and Arenas, E. (2002). Persephin-overexpressing neural stem cells regulate the function of nigral dopaminergic neurons and prevent their degeneration in a model of Parkinson's disease. *Mol. Cell. Neurosci.* **21**, 205–222.
- Almqvist, P. M., Åkesson, E., Wahlberg, L. U., Pschera, H., Seiger, Å. and Sundström, E. (1996). First trimester development of the human nigrostriatal dopamine system. *Exp. Neurol.* **139**, 227–237.
- Alvarez-Fischer, D., Fuchs, J., Castagner, F., Stettler, O., Massiani-Beaudoin, O., Moya, K. L., Bouillot, C., Oertel, W. H., Lombès, A., Faigle, W. et al. (2011). Engrailed protects mouse midbrain dopaminergic neurons against mitochondrial complex I insults. *Nat. Neurosci.* **14**, 1260–1266.
- Ambasudhan, R., Talantova, M., Coleman, R., Yuan, X., Zhu, S., Lipton, S. A. and Ding, S. (2011). Direct reprogramming of adult human fibroblasts to functional neurons under defined conditions. *Cell Stem Cell* **9**, 113–118.
- Andersson, E., Jensen, J. B., Parmar, M., Guillemot, F. and Björklund, A. (2006a). Development of the mesencephalic dopaminergic neuron system is compromised in the absence of neurogenin 2. *Development* **133**, 507–516.
- Andersson, E., Tryggvason, U., Deng, Q., Friling, S., Alekseenko, Z., Robert, B., Perlmann, T. and Ericson, J. (2006b). Identification of intrinsic determinants of midbrain dopamine neurons. *Cell* **124**, 393–405.
- Andersson, E. R., Prakash, N., Cajanek, L., Minina, E., Bryja, V., Bryjova, L., Yamaguchi, T. P., Hall, A. C., Wurst, W. and Arenas, E. (2008). Wnt5a regulates ventral midbrain morphogenesis and the development of A9-A10 dopaminergic cells in vivo. *PLoS ONE* **3**, e3517.
- Andersson, E. R., Salto, C., Villaseca, J. C., Cajanek, L., Yang, S., Bryjova, L., Nagy, I. I., Vainio, S. J., Ramirez, C., Bryja, V. et al. (2013). Wnt5a cooperates with canonical Wnts to generate midbrain dopaminergic neurons in vivo and in stem cells. *Proc. Natl. Acad. Sci. USA* **110**, E602–E610.
- Ang, S.-L. and Rossant, J. (1994). HNF-3 beta is essential for node and notochord formation in mouse development. *Cell* **78**, 561–574.
- Ang, S. L., Wierda, A., Wong, D., Stevens, K. A., Cascio, S., Rossant, J. and Zaret, K. S. (1993). The formation and maintenance of the definitive endoderm lineage in the mouse: involvement of HNF3/forkhead proteins. *Development* **119**, 1301–1315.
- Arenas, E. (2010). Towards stem cell replacement therapies for Parkinson's disease. *Biochem. Biophys. Res. Commun.* **396**, 152–156.
- Arenas, E. (2014). Wnt signaling in midbrain dopaminergic neuron development and regenerative medicine for Parkinson's disease. *J. Mol. Cell Biol.* **6**, 42–53.
- Arenas, E., Trupp, M., Åkerud, P. and Ibáñez, C. F. (1995). GDNF prevents degeneration and promotes the phenotype of brain noradrenergic neurons in vivo. *Neuron* **15**, 1465–1473.
- Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., McLauchlan, H., Klevernic, I., Arthur, J. S. C., Alessi, D. R. and Cohen, P. (2007). The selectivity of protein kinase inhibitors: a further update. *Biochem. J.* **408**, 297–315.
- Baquet, Z. C., Bickford, P. C. and Jones, K. R. (2005). Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta. *J. Neurosci.* **25**, 6251–6259.
- Basson, M. A., Echevarria, D., Ahn, C. P., Sudarov, A., Joyner, A. L., Mason, I. J., Martinez, S. and Martin, G. R. (2008). Specific regions within the embryonic midbrain and cerebellum require different levels of FGF signaling during development. *Development* **135**, 889–898.
- Beck, K. D., Valverde, J., Alexi, T., Poulsen, K., Moffat, B., Vandlen, R. A., Rosenthal, A. and Hefti, F. (1995). Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. *Nature* **373**, 339–341.
- Berninger, B., Costa, M. R., Koch, U., Schroeder, T., Sutor, B., Grothe, B. and Gotz, M. (2007). Functional properties of neurons derived from in vitro reprogrammed postnatal astroglia. *J. Neurosci.* **27**, 8654–8664.
- Björklund, A. and Hökfelt, T. (1983). *Handbook of Chemical Neuroanatomy*. Amsterdam; New York: Elsevier.
- Blaess, S., Bodea, G. O., Kabanova, A., Charet, S., Mugniery, E., Derouiche, A., Stephen, D. and Joyner, A. L. (2011). Temporal-spatial changes in Sonic Hedgehog expression and signaling reveal different potentials of ventral mesencephalic progenitors to populate distinct ventral midbrain nuclei. *Neural Dev.* **6**, 29.
- Bodea, G. O., Spille, J.-H., Abe, P., Andersson, A. S., Acker-Palmer, A., Stumm, R., Kubitscheck, U. and Blaess, S. (2014). Reelin and CXCL12 regulate distinct migratory behaviors during the development of the dopaminergic system. *Development* **141**, 661–673.
- Bonilla, S., Hall, A. C., Pinto, L., Attardo, A., Götz, M., Huttner, W. B. and Arenas, E. (2008). Identification of midbrain floor plate radial glia-like cells as dopaminergic progenitors. *Glia* **56**, 809–820.
- Brichta, L., Greengard, P. and Flajole, M. (2013). Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems. *Trends Neurosci.* **36**, 543–554.
- Briscoe, J. and Ericson, J. (1999). The specification of neuronal identity by graded Sonic Hedgehog signalling. *Semin. Cell Dev. Biol.* **10**, 353–362.
- Broccoli, V., Boncinelli, E. and Wurst, W. (1999). The caudal limit of Otx2 expression positions the isthmus organizer. *Nature* **401**, 164–168.
- Brown, A., Machan, J. T., Hayes, L. and Zervas, M. (2011). Molecular organization and timing of Wnt1 expression define cohorts of midbrain dopamine neuron progenitors in vivo. *J. Comp. Neurol.* **519**, 2978–3000.
- Byers, B., Cord, B., Nguyen, H. N., Schüle, B., Fenno, L., Lee, P. C., Deisseroth, K., Langston, J. W., Pera, R. R. and Palmer, T. D. (2011). SNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate alpha-synuclein and are susceptible to oxidative stress. *PLoS ONE* **6**, e26159.
- Caiazzo, M., Dell'Anno, M. T., Dvoretzka, E., Lazarevic, D., Taverna, S., Leo, D., Sotnikova, T. D., Menegon, A., Roncaglia, P., Colciago, G. et al. (2011). Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. *Nature* **476**, 224–227.

- Calabresi, P., Castrioto, A., Di Filippo, M. and Picconi, B. (2013). New experimental and clinical links between the hippocampus and the dopaminergic system in Parkinson's disease. *Lancet Neurol.* **12**, 811–821.
- Carlsson, A. (2001). A half-century of neurotransmitter research: impact on neurology and psychiatry. Nobel lecture. *Biosci. Rep.* **21**, 691–710.
- Carlsson, T., Carta, M., Winkler, C., Bjorklund, A. and Kirik, D. (2007). Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease. *J. Neurosci.* **27**, 8011–8022.
- Carlsson, T., Carta, M., Munoz, A., Mattsson, B., Winkler, C., Kirik, D. and Bjorklund, A. (2009). Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. *Brain* **132**, 319–335.
- Castaño, J., Menendez, P., Bruzos-Cidon, C., Straccia, M., Sousa, A., Zabaleta, L., Vazquez, N., Zubiarrain, A., Sonntag, K.-C., Ugedo, L. et al. (2014). Fast and efficient neural conversion of human hematopoietic cells. *Stem Cell Rep.* **3**, 1118–1131.
- Castelo-Branco, G., Wagner, J., Rodriguez, F. J., Kele, J., Sousa, K., Rawal, N., Pasolli, H. A., Fuchs, E., Kitajewski, J. and Arenas, E. (2003). Differential regulation of midbrain dopaminergic neuron development by Wnt-1, Wnt-3a, and Wnt-5a. *Proc. Natl. Acad. Sci. USA* **100**, 12747–12752.
- Castelo-Branco, G., Rawal, N. and Arenas, E. (2004). GSK-3 β inhibition/beta-catenin stabilization in ventral midbrain precursors increases differentiation into dopamine neurons. *J. Cell Sci.* **117**, 5731–5737.
- Castelo-Branco, G., Sousa, K. M., Bryja, V., Pinto, L., Wagner, J. and Arenas, E. (2006). Ventral midbrain glia express region-specific transcription factors and regulate dopaminergic neurogenesis through Wnt-5a secretion. *Mol. Cell. Neurosci.* **31**, 251–262.
- Chambers, S. M., Fasano, C. A., Papapetrou, E. P., Tomishima, M., Sadelain, M. and Studer, L. (2009). Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. *Nat. Biotechnol.* **27**, 275–280.
- Chanda, S., Ang, C. E., Davila, J., Pak, C., Mall, M., Lee, Q. Y., Ahlenius, H., Jung, S. W., Südhof, T. C. and Wernig, M. (2014). Generation of induced neuronal cells by the single reprogramming factor ASCL1. *Stem Cell Rep.* **3**, 282–296.
- Chao, J. and Nestler, E. J. (2004). Molecular neurobiology of drug addiction. *Annu. Rev. Med.* **55**, 113–132.
- Chaudhuri, K. R. and Schapira, A. H. V. (2009). Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. *Lancet Neurol.* **8**, 464–474.
- Chaudhuri, K. R., Healy, D. G. and Schapira, A. H. V. (2006). Non-motor symptoms of Parkinson's disease: diagnosis and management. *Lancet Neurol.* **5**, 235–245.
- Chi, C. L., Martinez, S., Wurst, W. and Martin, G. R. (2003). The isthmus organizer signal FGF8 is required for cell survival in the prospective midbrain and cerebellum. *Development* **130**, 2633–2644.
- Chiang, C., Litingtung, Y., Lee, E., Young, K. E., Corden, J. L., Westphal, H. and Beachy, P. A. (1996). Cyclopia and defective axial patterning in mice lacking Sonic hedgehog gene function. *Nature* **383**, 407–413.
- Choi-Lundberg, D. L., Lin, Q., Chang, Y.-N., Chiang, Y. L., Hay, C. M., Mohajeri, H., Davidson, B. L. and Bohn, M. C. (1997). Dopaminergic neurons protected from degeneration by GDNF gene therapy. *Science* **275**, 838–841.
- Chung, C. Y., Seo, H., Sonntag, K. C., Brooks, A., Lin, L. and Isacson, O. (2005a). Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. *Hum. Mol. Genet.* **14**, 1709–1725.
- Chung, S., Hedlund, E., Hwang, M., Kim, D. W., Shin, B.-S., Hwang, D.-Y., Kang, U. J., Isacson, O. and Kim, K.-S. (2005b). The homeodomain transcription factor Pitx3 facilitates differentiation of mouse embryonic stem cells into AHD2-expressing dopaminergic neurons. *Mol. Cell. Neurosci.* **28**, 241–252.
- Chung, S., Leung, A., Han, B.-S., Chang, M.-Y., Moon, J.-I., Kim, C.-H., Hong, S., Pruszk, J., Isacson, O. and Kim, K.-S. (2009). Wnt1-lmx1a forms a novel autoregulatory loop and controls midbrain dopaminergic differentiation synergistically with the SHH-FoxA2 pathway. *Cell Stem Cell* **5**, 646–658.
- Chung, C. Y., Khurana, V., Auluck, P. K., Tardiff, D. F., Mazzulli, J. R., Soldner, F., Bar, V., Lou, Y., Frey, Y., Cho, S. et al. (2013). Identification and rescue of alpha-synuclein toxicity in Parkinson patient-derived neurons. *Science* **342**, 983–987.
- Connolly, B. S. and Lang, A. E. (2014). Pharmacological treatment of Parkinson disease: a review. *JAMA* **311**, 1670–1683.
- Cooper, O., Seo, H., Andrabi, S., Guardia-Laguarta, C., Graziotto, J., Sundberg, M., McLean, J. R., Carrillo-Reid, L., Xie, Z., Osborn, T. et al. (2012). Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. *Sci. Transl. Med.* **4**, 141ra190.
- Courtois, E. T., Castillo, C. G., Seiz, E. G., Ramos, M., Bueno, C., Liste, I. and Martinez-Serrano, A. (2010). In vitro and in vivo enhanced generation of human A9 dopamine neurons from neural stem cells by Bcl-XL. *J. Biol. Chem.* **285**, 9881–9897.
- Dahlstroem, A. and Fuxe, K. (1964). Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons. *Acta Physiol. Scand. Suppl.* **232**, 231–255.
- Davis, R. L., Weintraub, H. and Lassar, A. B. (1987). Expression of a single transcribed cDNA converts fibroblasts to myoblasts. *Cell* **51**, 987–1000.
- De la Rossa, A., Bellone, C., Golding, B., Vitali, I., Moss, J., Toni, N., Lüscher, C. and Jabaudon, D. (2013). In vivo reprogramming of circuit connectivity in postmitotic neocortical neurons. *Nat. Neurosci.* **16**, 193–200.
- Decressac, M., Kadhodaei, B., Mattsson, B., Laguna, A., Perlmann, T. and Bjorklund, A. (2012). alpha-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. *Sci. Transl. Med.* **4**, 163ra156.
- Dell'Anno, M. T., Caiazzo, M., Leo, D., Dvoretzskova, E., Medrihan, L., Colasante, G., Giannelli, S., Theka, I., Russo, G., Mus, L. et al. (2014). Remote control of induced dopaminergic neurons in parkinsonian rats. *J. Clin. Invest.* **124**, 3215–3229.
- Demyanenko, G. P., Shibata, Y. and Maness, P. F. (2001). Altered distribution of dopaminergic neurons in the brain of L1 null mice. *Brain Res. Dev. Brain Res.* **126**, 21–30.
- Deng, Q., Andersson, E., Hedlund, E., Alekseenko, Z., Coppola, E., Panman, L., Millonig, J. H., Brunet, J.-F., Ericson, J. and Perlmann, T. (2011). Specific and integrated roles of Lmx1a, Lmx1b and Phox2a in ventral midbrain development. *Development* **138**, 3399–3408.
- Denham, M., Bye, C., Leung, J., Conley, B. J., Thompson, L. H. and Dottori, M. (2012). Glycogen synthase kinase 3 β and activin/nodal inhibition in human embryonic stem cells induces a pre-neuroepithelial state that is required for specification to a floor plate cell lineage. *Stem Cells* **30**, 2400–2411.
- Devine, M. J., Ryten, M., Vodicka, P., Thomson, A. J., Burdon, T., Houlden, H., Cavaleri, F., Nagano, M., Drummond, N. J., Taanman, J.-W. et al. (2011). Parkinson's disease induced pluripotent stem cells with triplication of the alpha-synuclein locus. *Nat. Commun.* **2**, 440.
- Di Giovannantonio, L. G., Di Salvio, M., Acampora, D., Prakash, N., Wurst, W. and Simeone, A. (2013). Otx2 selectively controls the neurogenesis of specific neuronal subtypes of the ventral tegmental area and compensates En1-dependent neuronal loss and MPTP vulnerability. *Dev. Biol.* **373**, 176–183.
- Di Salvio, M., Di Giovannantonio, L. G., Acampora, D., Prosperi, R., Omodei, D., Prakash, N., Wurst, W. and Simeone, A. (2010a). Otx2 controls neuron subtype identity in ventral tegmental area and antagonizes vulnerability to MPTP. *Nat. Neurosci.* **13**, 1481–1488.
- Di Salvio, M., Di Giovannantonio, L. G., Omodei, D., Acampora, D. and Simeone, A. (2010b). Otx2 expression is restricted to dopaminergic neurons of the ventral tegmental area in the adult brain. *Int. J. Dev. Biol.* **54**, 939–945.
- Doi, D., Samata, B., Katsukawa, M., Kikuchi, T., Morizane, A., Ono, Y., Sekiguchi, K., Nakagawa, M., Parmar, M. and Takahashi, J. (2014). Isolation of human induced pluripotent stem cell-derived dopaminergic progenitors by cell sorting for successful transplantation. *Stem Cell Rep.* **2**, 337–350.
- Ellisor, D., Rieser, C., Voelcker, B., Machan, J. T. and Zervas, M. (2012). Genetic dissection of midbrain dopamine neuron development in vivo. *Dev. Biol.* **372**, 249–262.
- Ericson, J., Morton, S., Kawakami, A., Roelink, H. and Jessell, T. M. (1996). Two critical periods of Sonic Hedgehog signaling required for the specification of motor neuron identity. *Cell* **87**, 661–673.
- Evans, J. R., Mason, S. L. and Barker, R. A. (2012). Current status of clinical trials of neural transplantation in Parkinson's disease. *Prog. Brain Res.* **200**, 169–198.
- Falk, A., Koch, P., Kesavan, J., Takashima, Y., Ladewig, J., Alexander, M., Wiskow, O., Taylor, J., Trotter, M., Pollard, S. et al. (2012). Capture of neuroepithelial-like stem cells from pluripotent stem cells provides a versatile system for in vitro production of human neurons. *PLoS ONE* **7**, e29597.
- Fasano, C. A., Chambers, S. M., Lee, G., Tomishima, M. J. and Studer, L. (2010). Efficient derivation of functional floor plate tissue from human embryonic stem cells. *Cell Stem Cell* **6**, 336–347.
- Ferri, A. L. M., Lin, W., Mavromatakis, Y. E., Wang, J. C., Sasaki, H., Whitsett, J. A. and Ang, S.-L. (2007). Foxa1 and Foxa2 regulate multiple phases of midbrain dopaminergic neuron development in a dosage-dependent manner. *Development* **134**, 2761–2769.
- Flores, C., Manitt, C., Rodaros, D., Thompson, K. M., Rajabi, H., Luk, K. C., Tritsch, N. X., Sadikot, A. F., Stewart, J. and Kennedy, T. E. (2005). Netrin receptor deficient mice exhibit functional reorganization of dopaminergic systems and do not sensitize to amphetamine. *Mol. Psychiatry* **10**, 606–612.
- Foix, C. and Nicoses, J. (1925). *Anatomie cérébrale; les noyaux gris centraux et la région mésencéphalo-sous-optique*. Paris: Masson et cie.
- Fox, S. H., Brothie, J. M. and Lang, A. E. (2008). Non-dopaminergic treatments in development for Parkinson's disease. *Lancet Neurol.* **7**, 927–938.
- Freeman, T. B., Spence, M. S., Boss, B. D., Spector, D. H., Strecker, R. E., Olanow, C. W. and Kordower, J. H. (1991). Development of dopaminergic neurons in the human substantia nigra. *Exp. Neurol.* **113**, 344–353.
- Friling, S., Andersson, E., Thompson, L. H., Jonsson, M. E., Hebsgaard, J. B., Nanou, E., Alekseenko, Z., Marklund, U., Kjellander, S., Volakakis, N. et al. (2009). Efficient production of mesencephalic dopamine neurons by Lmx1a expression in embryonic stem cells. *Proc. Natl. Acad. Sci. USA* **106**, 7613–7618.
- Frim, D. M., Uhler, T. A., Galpern, W. R., Beal, M. F., Breakefield, X. O. and Isacson, O. (1994). Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. *Proc. Natl. Acad. Sci. USA* **91**, 5104–5108.

- Ganat, Y. M., Calder, E. L., Kriks, S., Nelander, J., Tu, E. Y., Jia, F., Battista, D., Harrison, N., Parmar, M., Tomishima, M. J. et al. (2012). Identification of embryonic stem cell-derived midbrain dopaminergic neurons for engraftment. *J. Clin. Invest.* **122**, 2928–2939.
- Gash, D. M., Zhang, Z., Ovadia, A., Cass, W. A., Yi, A., Simmerman, L., Russell, D., Martin, D., Lapchak, P. A., Collins, F. et al. (1996). Functional recovery in parkinsonian monkeys treated with GDNF. *Nature* **380**, 252–255.
- Gil, M., McKinney, C., Lee, M. K., Eells, J. B., Phyllaier, M. A. and Nikodem, V. M. (2007). Regulation of GTP cyclohydrolase I expression by orphan receptor Nurr1 in cell culture and in vivo. *J. Neurochem.* **101**, 142–150.
- Graham, D. G. (1979). On the origin and significance of neuromelanin. *Arch. Pathol. Lab. Med.* **103**, 359–362.
- Grande, A., Sumiyoshi, K., López-Juárez, A., Howard, J., Sakthivel, B., Aronow, B., Campbell, K. and Nakafuku, M. (2013). Environmental impact on direct neuronal reprogramming in vivo in the adult brain. *Nat. Commun.* **4**, 2373.
- Grealish, S., Jonsson, M. E., Li, M., Kirik, D., Björklund, A. and Thompson, L. H. (2010). The A9 dopamine neuron component in grafts of ventral mesencephalon is an important determinant for recovery of motor function in a rat model of Parkinson's disease. *Brain* **133**, 482–495.
- Grealish, S., Diguett, E., Kirkeby, A., Mattsson, B., Heuer, A., Bramouille, Y., Van Camp, N., Perrier, A. L., Hantraye, P., Björklund, A. et al. (2014). Human ESC-derived dopamine neurons show similar preclinical efficacy and potency to fetal neurons when grafted in a rat model of Parkinson's disease. *Cell Stem Cell* **15**, 653–665.
- Guo, Z., Zhang, L., Wu, Z., Chen, Y., Wang, F. and Chen, G. (2014). In Vivo direct reprogramming of reactive glial cells into functional neurons after brain injury and in an Alzheimer's disease model. *Cell Stem Cell* **14**, 188–202.
- Hallett, P. J., Cooper, O., Sadi, D., Robertson, H., Mendez, I. and Isacson, O. (2014). Long-term health of dopaminergic neuron transplants in Parkinson's disease patients. *Cell Rep.* **7**, 1755–1761.
- Halliday, G., Lees, A. and Stern, M. (2011). Milestones in Parkinson's disease—clinical and pathologic features. *Mov. Disord.* **26**, 1015–1021.
- Hanaway, J., McConnell, J. A. and Netsky, M. G. (1971). Histogenesis of the substantia nigra, ventral tegmental area of Tsai and interpeduncular nucleus: an autoradiographic study of the mesencephalon in the rat. *J. Comp. Neurol.* **142**, 59–73.
- Hargus, G., Cooper, O., Deleidi, M., Levy, A., Lee, K., Marlow, E., Yow, A., Soldner, F., Hockemeyer, D., Hallett, P. J. et al. (2010). Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats. *Proc. Natl. Acad. Sci. USA* **107**, 15921–15926.
- Hassler, R. (1938). Zur Pathologie der Paralysis agitans und des postenzephalitischen Parkinsonismus. *J. Psychiatr. Neurol.* **48**, 387–476.
- Hayes, L., Zhang, Z., Albert, P., Zervas, M. and Ahn, S. (2011). Timing of Sonic hedgehog and Gli1 expression segregates midbrain dopamine neurons. *J. Comp. Neurol.* **519**, 3001–3018.
- Heinrich, C., Blum, R., Gascón, S., Masserdotti, G., Tripathi, P., Sánchez, R., Tiedt, S., Schroeder, T., Götz, M. and Berninger, B. (2010). Directing astroglia from the cerebral cortex into subtype specific functional neurons. *PLoS Biol.* **8**, e1000373.
- Heinrich, C., Gascón, S., Masserdotti, G., Lepier, A., Sanchez, R., Simon-Ebert, T., Schroeder, T., Götz, M. and Berninger, B. (2011). Generation of subtype-specific neurons from postnatal astroglia of the mouse cerebral cortex. *Nat. Protoc.* **6**, 214–228.
- Heinrich, C., Bergami, M., Gascón, S., Lepier, A., Viganò, F., Dimou, L., Sutor, B., Berninger, B. and Götz, M. (2014). Sox2-mediated conversion of NG2 Glia into induced neurons in the injured adult cerebral cortex. *Stem Cell Rep.* **3**, 1000–1014.
- Heins, N., Malatesta, P., Cecconi, F., Nakafuku, M., Tucker, K. L., Hack, M. A., Chapouton, P., Barde, Y.-A. and Götz, M. (2002). Glial cells generate neurons: the role of the transcription factor Pax6. *Nat. Neurosci.* **5**, 308–315.
- Hockemeyer, D., Soldner, F., Beard, C., Gao, Q., Mitalipova, M., DeKelver, R. C., Katibah, G. E., Amora, R., Boydston, E. A., Zeitler, B. et al. (2009). Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. *Nat. Biotechnol.* **27**, 851–857.
- Horger, B. A., Nishimura, M. C., Armanini, M. P., Wang, L. C., Poulsen, K. T., Rosenblad, C., Kirik, D., Moffat, B., Simmons, L., Johnson, E. Jr. et al. (1998). Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. *J. Neurosci.* **18**, 4929–4937.
- Hornykiewicz, O. (1978). Psychopharmacological implications of dopamine and dopamine antagonists: a critical evaluation of current evidence. *Neuroscience* **3**, 773–783.
- Horowski, R., Horowski, L., Phil, C., Vogel, S., Poewe, W. and Kielhorn, F.-W. (1995). An essay on Wilhelm Von Humboldt and the shaking palsy: first comprehensive description of Parkinson's disease by a patient. *Neurology* **45**, 565–568.
- Hur, E.-M. and Zhou, F.-Q. (2010). GSK3 signalling in neural development. *Nat. Rev. Neurosci.* **11**, 539–551.
- Hwang, D.-Y., Ardayfio, P., Kang, U. J., Semina, E. V. and Kim, K.-S. (2003). Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice. *Brain Res. Mol. Brain Res.* **114**, 123–131.
- Hyman, C., Hofer, M., Barde, Y.-A., Juhasz, M., Yancopoulos, G. D., Squinto, S. P. and Lindsay, R. M. (1991). BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. *Nature* **350**, 230–232.
- Jacobs, F. M. J., Smits, S. M., Noorlander, C. W., von Oerthel, L., van der Linden, A. J. A., Burbach, J. P. H. and Smidt, M. P. (2007). Retinoic acid counteracts developmental defects in the substantia nigra caused by Pitx3 deficiency. *Development* **134**, 2673–2684.
- Jacobs, F. M. J., van Erp, S., van der Linden, A. J. A., von Oerthel, L., Burbach, J. P. H. and Smidt, M. P. (2009). Pitx3 potentiates Nurr1 in dopamine neuron terminal differentiation through release of SMRT-mediated repression. *Development* **136**, 531–540.
- Jacobs, F. M. J., Veenfliet, J. V., Almira, W. H., Hoekstra, E. J., von Oerthel, L., van der Linden, A. J. A., Neijts, R., Koerkamp, M. G., van Leenen, D., Holstege, F. C. P. et al. (2011). Retinoic acid-dependent and -independent gene-regulatory pathways of Pitx3 in meso-diencephalic dopaminergic neurons. *Development* **138**, 5213–5222.
- Jaeger, I., Arber, C., Rösner-Janiczek, J. R., Kuechler, J., Pritzsche, D., Chen, I.-C., Naveenan, T., Ungless, M. A. and Li, M. (2011). Temporally controlled modulation of FGF/ERK signaling directs midbrain dopaminergic neural progenitor fate in mouse and human pluripotent stem cells. *Development* **138**, 4363–4374.
- Jain, S. and Heutink, P. (2010). From single genes to gene networks: high-throughput-high-content screening for neurological disease. *Neuron* **68**, 207–217.
- Jankovic, J. and Aguilar, L. G. (2008). Current approaches to the treatment of Parkinson's disease. *Neuropsychiatr. Dis. Treatment* **4**, 743–757.
- Jankovic, J. and Poewe, W. (2012). Therapies in Parkinson's disease. *Curr. Opin. Neurol.* **25**, 433–447.
- Jankovic, J., Chen, S. and Le, W. D. (2005). The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease. *Prog. Neurobiol.* **77**, 128–138.
- Jellinger, K. A. (1991). Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. *Mol. Chem. Neuropathol.* **14**, 153–197.
- Joksimovic, M., Anderegg, A., Roy, A., Campochiaro, L., Yun, B., Kittappa, R., McKay, R. and Awatramani, R. (2009a). Spatiotemporally separable Shh domains in the midbrain define distinct dopaminergic progenitor pools. *Proc. Natl. Acad. Sci. USA* **106**, 19185–19190.
- Joksimovic, M., Yun, B. A., Kittappa, R., Anderegg, A. M., Chang, W. W., Taketo, M. M., McKay, R. D. G. and Awatramani, R. B. (2009b). Wnt antagonism of Shh facilitates midbrain floor plate neurogenesis. *Nat. Neurosci.* **12**, 125–131.
- Jönsson, M. E., Ono, Y., Björklund, A. and Thompson, L. H. (2009). Identification of transplantable dopamine neuron precursors at different stages of midbrain neurogenesis. *Exp. Neurol.* **219**, 341–354.
- Joseph, B., Wallen-Mackenzie, A., Benoit, G., Murata, T., Joodmardi, E., Okret, S. and Perlmann, T. (2003). p57(Kip2) cooperates with Nurr1 in developing dopamine cells. *Proc. Natl. Acad. Sci. USA* **100**, 15619–15624.
- Joyner, A. L., Liu, A. and Millet, S. (2000). Otx2, Gbx2 and Fgf8 interact to position and maintain a mid-hindbrain organizer. *Curr. Opin. Cell Biol.* **12**, 736–741.
- Kadkhodaei, B., Ito, T., Joodmardi, E., Mattsson, B., Rouillard, C., Carta, M., Muramatsu, S.-I., Sumi-Ichinose, C., Nomura, T., Metzger, D. et al. (2009). Nurr1 is required for maintenance of maturing and adult midbrain dopamine neurons. *J. Neurosci.* **29**, 15923–15932.
- Kadoshima, T., Sakaguchi, H., Nakano, T., Soen, M., Ando, S., Eiraku, M. and Sasai, Y. (2013). Self-organization of axial polarity, inside-out layer pattern, and species-specific progenitor dynamics in human ES cell-derived neocortex. *Proc. Natl. Acad. Sci. USA* **110**, 20284–20289.
- Kang, W.-Y., Kim, S.-S., Cho, S.-K., Kim, S., Suh-Kim, H. and Lee, Y.-D. (2010). Migratory defect of mesencephalic dopaminergic neurons in developing reeler mice. *Anat. Cell Biol.* **43**, 241–251.
- Karow, M., Sánchez, R., Schichor, C., Masserdotti, G., Ortega, F., Heinrich, C., Gascon, S., Khan, M. A., Lie, D. C., Dellavalle, A. et al. (2012). Reprogramming of pericyte-derived cells of the adult human brain into induced neuronal cells. *Cell Stem Cell* **11**, 471–476.
- Kawano, H., Ohyama, K., Kawamura, K. and Nagatsu, I. (1995). Migration of dopaminergic neurons in the embryonic mesencephalon of mice. *Brain Res. Dev. Brain Res.* **86**, 101–113.
- Kawasaki, H., Mizuseki, K., Nishikawa, S., Kaneko, S., Kuwana, Y., Nakanishi, S., Nishikawa, S.-I. and Sasai, Y. (2000). Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity. *Neuron* **28**, 31–40.
- Kele, J., Simplicio, N., Ferri, A. L. M., Mira, H., Guillemot, F., Arenas, E. and Ang, S.-L. (2006). Neurogenin 2 is required for the development of ventral midbrain dopaminergic neurons. *Development* **133**, 495–505.
- Kim, J.-H., Auerbach, J. M., Rodríguez-Gómez, J. A., Velasco, I., Gavin, D., Lumelsky, N., Lee, S.-H., Nguyen, J., Sánchez-Pernaute, R., Bankiewicz, K. et al. (2002). Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. *Nature* **418**, 50–56.
- Kim, J., Su, S. C., Wang, H., Cheng, A. W., Cassady, J. P., Lodato, M. A., Lengner, C. J., Chung, C.-Y., Dawlaty, M. M., Tsai, L.-H. et al. (2011). Functional integration of dopaminergic neurons directly converted from mouse fibroblasts. *Cell Stem Cell* **9**, 413–419.
- Kirkeby, A., Grealish, S., Wolf, D. A., Nelander, J., Wood, J., Lundblad, M., Lindvall, O. and Parmar, M. (2012). Generation of regionally specified neural

- progenitors and functional neurons from human embryonic stem cells under defined conditions. *Cell Rep.* **1**, 703–714.
- Kiskinis, E. and Eggan, K. (2010). Progress toward the clinical application of patient-specific pluripotent stem cells. *J. Clin. Invest.* **120**, 51–59.
- Koch, P., Opitz, T., Steinbeck, J. A., Ladewig, J. and Brustle, O. (2009). A rosette-type, self-renewing human ES cell-derived neural stem cell with potential for in vitro instruction and synaptic integration. *Proc. Natl. Acad. Sci. USA* **106**, 3225–3230.
- Kordower, J. H., Emborg, M. E., Bloch, J., Ma, S. Y., Chu, Y., Leventhal, L., McBride, J., Chen, E.-Y., Palfi, S., Roitberg, B. Z. et al. (2000). Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. *Science* **290**, 767–773.
- Kriegstein, K., Farkas, L. and Unsicker, K. (1998). TGF-beta regulates the survival of ciliary ganglionic neurons synergistically with ciliary neurotrophic factor and neurotrophins. *J. Neurobiol.* **37**, 563–572.
- Kriks, S., Shim, J.-W., Piao, J., Ganat, Y. M., Wakeman, D. R., Xie, Z., Carrillo-Reid, L., Auyeung, G., Antonacci, C., Buch, A. et al. (2011). Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. *Nature* **480**, 547–551.
- Ladewig, J., Mertens, J., Kesavan, J., Doerr, J., Poppe, D., Glaue, F., Herms, S., Wernet, P., Kögler, G., Müller, F.-J. et al. (2012). Small molecules enable highly efficient neuronal conversion of human fibroblasts. *Nat. Methods* **9**, 575–578.
- Ladewig, J., Koch, P. and Brustle, O. (2013). Leveling Waddington: the emergence of direct programming and the loss of cell fate hierarchies. *Nat. Rev. Mol. Cell Biol.* **14**, 225–236.
- Lancaster, M. A., Renner, M., Martin, C.-A., Wenzel, D., Bicknell, L. S., Hurler, M. E., Homfray, T., Penninger, J. M., Jackson, A. P. and Knoblich, J. A. (2013). Cerebral organoids model human brain development and microcephaly. *Nature* **501**, 373–379.
- Le, W.-d., Conneely, O. M., Zou, L., He, Y., Saucedo-Cardenas, O., Jankovic, J., Mosier, D. R. and Appel, S. H. (1999). Selective agenesis of mesencephalic dopaminergic neurons in Nurr1-deficient mice. *Exp. Neurol.* **159**, 451–458.
- Lee, S.-H., Lumelsky, N., Studer, L., Auerbach, J. M. and McKay, R. D. (2000). Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells. *Nat. Biotechnol.* **18**, 675–679.
- Lees, A. J., Hardy, J. and Revesz, T. (2009). Parkinson's disease. *Lancet* **373**, 2055–2066.
- Lin, L. F., Doherty, D. H., Lile, J. D., Bektess, S. and Collins, F. (1993). GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. *Science* **260**, 1130–1132.
- Lin, W., Metzke, E., Mavromatakis, Y. E., Gao, N., Balaskas, N., Sasaki, H., Briscoe, J., Whitsett, J. A., Goulding, M., Kaestner, K. H. et al. (2009). Foxa1 and Foxa2 function both upstream of and cooperatively with Lmx1a and Lmx1b in a feedforward loop promoting mesodiencephalic dopaminergic neuron development. *Dev. Biol.* **333**, 386–396.
- Lindholm, P., Voutilainen, M. H., Laurén, J., Peränen, J., Leppänen, V.-M., Andressoo, J.-O., Lindahl, M., Janhunen, S., Kalkkinen, N., Timmusk, T. et al. (2007). Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. *Nature* **448**, 73–77.
- Lindvall, O. and Björklund, A. (2004). Cell therapy in Parkinson's disease. *NeuroRx* **1**, 382–393.
- Lindvall, O. and Björklund, A. (2011). Cell therapeutics in Parkinson's disease. *Neurotherapeutics* **8**, 539–548.
- Liu, G.-H., Qu, J., Suzuki, K., Nivet, E., Li, M., Montserrat, N., Yi, F., Xu, X., Ruiz, S., Zhang, W. et al. (2012a). Progressive degeneration of human neural stem cells caused by pathogenic LRRK2. *Nature* **491**, 603–607.
- Liu, X., Li, F., Stubblefield, E. A., Blanchard, B., Richards, T. L., Larson, G. A., He, Y., Huang, Q., Tan, A.-C., Zhang, D. et al. (2012b). Direct reprogramming of human fibroblasts into dopaminergic neuron-like cells. *Cell Res.* **22**, 321–332.
- Livesey, F. J. and Hunt, S. P. (1997). Netrin and netrin receptor expression in the embryonic mammalian nervous system suggests roles in retinal, striatal, nigral, and cerebellar development. *Mol. Cell. Neurosci.* **8**, 417–429.
- Lloyd, K. and Hornykiewicz, O. (1970). Parkinson's disease: activity of L-dopa decarboxylase in discrete brain regions. *Science* **170**, 1212–1213.
- Maciacyk, J., Singec, I., Maciacyk, D. and Nikkha, G. (2008). Combined use of BDNF, ascorbic acid, low oxygen, and prolonged differentiation time generates tyrosine hydroxylase-expressing neurons after long-term in vitro expansion of human fetal midbrain precursor cells. *Exp. Neurol.* **213**, 354–362.
- Maetzel, D., Sarkar, S., Wang, H., Abi-Mosleh, L., Xu, P., Cheng, A. W., Gao, Q., Mitalipova, M. and Jaenisch, R. (2014). Genetic and chemical correction of cholesterol accumulation and impaired autophagy in hepatic and neural cells derived from Niemann-Pick Type C patient-specific iPS cells. *Stem Cell Rep.* **2**, 866–880.
- Marchand, R. and Poirier, L. J. (1983). Isthmic origin of neurons of the rat substantia nigra. *Neuroscience* **9**, 373–381.
- Marro, S., Pang, Z. P., Yang, N., Tsai, M.-C., Qu, K., Chang, H. Y., Südhof, T. C. and Wernig, M. (2011). Direct lineage conversion of terminally differentiated hepatocytes to functional neurons. *Cell Stem Cell* **9**, 374–382.
- Marti, E., Bumcrot, D. A., Takada, R. and McMahon, A. P. (1995). Requirement of 19K form of Sonic hedgehog for induction of distinct ventral cell types in CNS explants. *Nature* **375**, 322–325.
- Martinez, S., Crossley, P. H., Cobos, I., Rubenstein, J. L. and Martin, G. R. (1999). FGF8 induces formation of an ectopic isthmus organizer and isthmocerebellar development via a repressive effect on Otx2 expression. *Development* **126**, 1189–1200.
- Maxwell, S. L., Ho, H.-Y., Kuehner, E., Zhao, S. and Li, M. (2005). Pitx3 regulates tyrosine hydroxylase expression in the substantia nigra and identifies a subgroup of mesencephalic dopaminergic progenitor neurons during mouse development. *Dev. Biol.* **282**, 467–479.
- Mazzulli, J. R., Xu, Y.-H., Sun, Y., Knight, A. L., McLean, P. J., Caldwell, G. A., Sidransky, E., Grabowski, G. A. and Krainc, D. (2011). Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. *Cell* **146**, 37–52.
- McMahon, A. P. and Bradley, A. (1990). The Wnt-1 (int-1) proto-oncogene is required for development of a large region of the mouse brain. *Cell* **62**, 1073–1085.
- McMahon, A. P., Joyner, A. L., Bradley, A. and McMahon, J. A. (1992). The midbrain-hindbrain phenotype of Wnt-1/Wnt-1- mice results from stepwise deletion of engrailed-expressing cells by 9.5 days postcoitum. *Cell* **69**, 581–595.
- Metzakopian, E., Lin, W., Salmon-Divon, M., Dvinge, H., Andersson, E., Ericson, J., Perlmann, T., Whitsett, J. A., Bertone, P. and Ang, S.-L. (2012). Genome-wide characterization of Foxa2 targets reveals upregulation of floor plate genes and repression of ventrolateral genes in midbrain dopaminergic progenitors. *Development* **139**, 2625–2634.
- Millet, S., Campbell, K., Epstein, D. J., Losos, K., Harris, E. and Joyner, A. L. (1999). A role for Gbx2 in repression of Otx2 and positioning the mid/hindbrain organizer. *Nature* **401**, 161–164.
- Millonig, J. H., Millen, K. J. and Hatten, M. E. (2000). The mouse Dreher gene Lmx1a controls formation of the roof plate in the vertebrate CNS. *Nature* **403**, 764–769.
- Moore, M. W., Klein, R. D., Fariñas, I., Sauer, H., Armanini, M., Phillips, H., Reichardt, L. F., Ryan, A. M., Carver-Moore, K. and Rosenthal, A. (1996). Renal and neuronal abnormalities in mice lacking GDNF. *Nature* **382**, 76–79.
- Nakatani, T., Kumai, M., Mizuhara, E., Minaki, Y. and Ono, Y. (2010). Lmx1a and Lmx1b cooperate with Foxa2 to coordinate the specification of dopaminergic neurons and control of floor plate cell differentiation in the developing mesencephalon. *Dev. Biol.* **339**, 101–113.
- Nelander, J., Hebsgaard, J. B. and Parmar, M. (2009). Organization of the human embryonic ventral mesencephalon. *Gene Expr. Patterns* **9**, 555–561.
- Nguyen, H. N., Byers, B., Cord, B., Shcheglovitov, A., Byrne, J., Gujar, P., Kee, K., Schüle, B., Dolmetsch, R. E., Langston, W. et al. (2011). LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. *Cell Stem Cell* **8**, 267–280.
- Nishikawa, S., Goto, S., Yamada, K., Hamasaki, T. and Ushio, Y. (2003). Lack of Reelin causes malpositioning of nigral dopaminergic neurons: evidence from comparison of normal and Reelin(r) mutant mice. *J. Comp. Neurol.* **461**, 166–173.
- Niu, W., Zang, T., Zou, Y., Fang, S., Smith, D. K., Bachoo, R. and Zhang, C.-L. (2013). In vivo reprogramming of astrocytes to neuroblasts in the adult brain. *Nat. Cell Biol.* **15**, 1164–1175.
- Nunes, I., Tovmasian, L. T., Silva, R. M., Burke, R. E. and Goff, S. P. (2003). Pitx3 is required for development of substantia nigra dopaminergic neurons. *Proc. Natl. Acad. Sci. USA* **100**, 4245–4250.
- Ohshima, K., Kawano, H., Asou, H., Fukuda, T., Oohira, A., Uyemura, K. and Kawamura, K. (1998). Coordinate expression of L1 and 6B4 proteoglycan/phosphacan is correlated with the migration of mesencephalic dopaminergic neurons in mice. *Brain Res. Dev. Brain Res.* **107**, 219–226.
- Omodei, D., Acampora, D., Mancuso, P., Prakash, N., Di Giovannantonio, L. G., Wurst, W. and Simeone, A. (2008). Anterior-posterior graded response to Otx2 controls proliferation and differentiation of dopaminergic progenitors in the ventral mesencephalon. *Development* **135**, 3459–3470.
- Ono, Y., Nakatani, T., Sakamoto, Y., Mizuhara, E., Minaki, Y., Kumai, M., Hamaguchi, A., Nishimura, M., Inoue, Y., Hayashi, H. et al. (2007). Differences in neurogenic potential in floor plate cells along an anteroposterior location: midbrain dopaminergic neurons originate from mesencephalic floor plate cells. *Development* **134**, 3213–3225.
- Ono, Y., Nakatani, T., Minaki, Y. and Kumai, M. (2010). The basic helix-loop-helix transcription factor Noto3 controls neurogenic activity in mesencephalic floor plate cells. *Development* **137**, 1897–1906.
- Pang, Z. P., Yang, N., Vierbuchen, T., Ostermeier, A., Fuentes, D. R., Yang, T. Q., Citri, A., Sebastiano, V., Marro, S., Südhof, T. C. et al. (2011). Induction of human neuronal cells by defined transcription factors. *Nature* **476**, 220–223.
- Panman, L., Papatianou, M., Laguna, A., Oosterveen, T., Volakakis, N., Acampora, D., Kurtsdotter, I., Yoshitake, T., Kehr, J., Joodmardi, E. et al. (2014). Sox6 and Otx2 control the specification of substantia nigra and ventral tegmental area dopamine neurons. *Cell Rep.* **8**, 1018–1025.
- Parish, C. L., Castelo-Branco, G., Rawal, N., Tonnesen, J., Sorensen, A. T., Salto, C., Kokaia, M., Lindvall, O. and Arenas, E. (2008). Wnt5a-treated midbrain neural stem cells improve dopamine cell replacement therapy in parkinsonian mice. *J. Clin. Invest.* **118**, 149–160.

- Park, C.-H., Minn, Y.-K., Lee, J.-Y., Choi, D. H., Chang, M.-Y., Shim, J.-W., Ko, J.-Y., Koh, H.-C., Kang, M. J., Kang, J. S. et al. (2005). In vitro and in vivo analyses of human embryonic stem cell-derived dopamine neurons. *J. Neurochem.* **92**, 1265–1276.
- Pascual, A., Hidalgo-Figueroa, M., Piruat, J. I., Pintado, C. O., Gómez-Díaz, R. and López-Barneo, J. (2008). Absolute requirement of GDNF for adult catecholaminergic neuron survival. *Nat. Neurosci.* **11**, 755–761.
- Peng, C., Aron, L., Klein, R., Li, M., Wurst, W., Prakash, N. and Le, W. (2011). Pitx3 is a critical mediator of GDNF-induced BDNF expression in nigrostriatal dopaminergic neurons. *J. Neurosci.* **31**, 12802–12815.
- Perrier, A. L., Tabar, V., Barberi, T., Rubio, M. E., Bruses, J., Topf, N., Harrison, N. L. and Studer, L. (2004). Derivation of midbrain dopamine neurons from human embryonic stem cells. *Proc. Natl. Acad. Sci. USA* **101**, 12543–12548.
- Petrova, P. S., Raibekas, A., Pevsner, J., Vigo, N., Anafi, M., Moore, M. K., Peaire, A. E., Shridhar, V., Smith, D. I., Kelly, J. et al. (2003). MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons. *J. Mol. Neurosci.* **20**, 173–188.
- Pfisterer, U., Kirkeby, A., Torper, O., Wood, J., Nelander, J., Dufour, A., Bjorklund, A., Lindvall, O., Jakobsson, J. and Parmar, M. (2011). Direct conversion of human fibroblasts to dopaminergic neurons. *Proc. Natl. Acad. Sci. USA* **108**, 10343–10348.
- Pichel, J. G., Shen, L., Sheng, H. Z., Granholm, A.-C., Drago, J., Grinberg, A., Lee, E. J., Huang, S. P., Saarma, M., Hoffer, B. J. et al. (1996). Defects in enteric innervation and kidney development in mice lacking GDNF. *Nature* **382**, 73–76.
- Placzek, M. and Briscoe, J. (2005). The floor plate: multiple cells, multiple signals. *Nat. Rev. Neurosci.* **6**, 230–240.
- Politis, M., Wu, K., Loane, C., Quinn, N. P., Brooks, D. J., Rehnacrona, S., Bjorklund, A., Lindvall, O. and Piccini, P. (2010). Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. *Sci. Transl. Med.* **2**, 38ra46.
- Poulin, J.-F., Zou, J., Drouin-Ouellet, J., Kim, K.-Y. A., Cicchetti, F. and Awatramani, R. B. (2014). Defining midbrain dopaminergic neuron diversity by single-cell gene expression profiling. *Cell Rep.* **9**, 930–943.
- Poulsen, K. T., Armanini, M. P., Klein, R. D., Hynes, M. A., Phillips, H. S. and Rosenthal, A. (1994). TGF beta 2 and TGF beta 3 are potent survival factors for midbrain dopaminergic neurons. *Neuron* **13**, 1245–1252.
- Prakash, N., Brodski, C., Naserke, T., Puelles, E., Gogoi, R., Hall, A., Panhuysen, M., Echevarria, D., Sussel, L., Weisenhorn, D. M. V. et al. (2006). A Wnt1-regulated genetic network controls the identity and fate of midbrain-dopaminergic progenitors in vivo. *Development* **133**, 89–98.
- Pruszak, J., Sonntag, K.-C., Aung, M. H., Sanchez-Pernaute, R. and Isacson, O. (2007). Markers and methods for cell sorting of human embryonic stem cell-derived neural cell populations. *Stem Cells* **25**, 2257–2268.
- Puelles, E., Annino, A., Tuorto, F., Usiello, A., Acampora, D., Czerny, T., Brodski, C., Ang, S.-L., Wurst, W. and Simeone, A. (2004). Otx2 regulates the extent, identity and fate of neuronal progenitor domains in the ventral midbrain. *Development* **131**, 2037–2048.
- Qiang, L., Fujita, R., Yamashita, T., Angulo, S., Rhinn, H., Rhee, D., Doege, C., Chau, L., Aubry, L., Vanti, W. B. et al. (2011). Directed conversion of Alzheimer's disease patient skin fibroblasts into functional neurons. *Cell* **146**, 359–371.
- Ramos-Moreno, T., Castillo, C. G. and Martínez-Serrano, A. (2012). Long term behavioral effects of functional dopaminergic neurons generated from human neural stem cells in the rat 6-OH-DA Parkinson's disease model. Effects of the forced expression of BCL-X(L). *Behav. Brain Res.* **232**, 225–232.
- Reinhardt, P., Schmid, B., Burbulla, L. F., Schöndorf, D. C., Wagner, L., Glatza, M., Höing, S., Hargus, G., Heck, S. A., Dhingra, A. et al. (2013). Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. *Cell Stem Cell* **12**, 354–367.
- Rhinn, M., Dierich, A., Shawlot, W., Behringer, R. R., Le Meur, M. and Ang, S. L. (1998). Sequential roles for Otx2 in visceral endoderm and neuroectoderm for forebrain and midbrain induction and specification. *Development* **125**, 845–856.
- Rhinn, M., Dierich, A., Le Meur, M. and Ang, S. (1999). Cell autonomous and non-cell autonomous functions of Otx2 in patterning the rostral brain. *Development* **126**, 4295–4304.
- Riaz, S. S., Jauniaux, E., Stern, G. M. and Bradford, H. F. (2002). The controlled conversion of human neural progenitor cells derived from foetal ventral mesencephalon into dopaminergic neurons in vitro. *Brain Res. Dev. Brain Res.* **136**, 27–34.
- Ribeiro, D., Laguna Goya, R., Ravindran, G., Vuono, R., Parish, C. L., Foldi, C., Piroth, T., Yang, S., Parmar, M., Nikkhah, G. et al. (2012). Efficient expansion and dopaminergic differentiation of human fetal ventral midbrain neural stem cells by midbrain morphogens. *Neurobiol. Dis.* **49C**, 118–127.
- Riedl, S. J. and Salvesen, G. S. (2007). The apoptosome: signalling platform of cell death. *Nat. Rev. Mol. Cell Biol.* **8**, 405–413.
- Roelink, H., Porter, J. A., Chiang, C., Tanabe, Y., Chang, D. T., Beachy, P. A. and Jessell, T. M. (1995). Floor plate and motor neuron induction by different concentrations of the amino-terminal cleavage product of sonic hedgehog autoproteolysis. *Cell* **81**, 445–455.
- Roeper, J. (2013). Dissecting the diversity of midbrain dopamine neurons. *Trends Neurosci.* **36**, 336–342.
- Rosenblad, C., Martínez-Serrano, A. and Björklund, A. (1998). Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease. *Neuroscience* **82**, 129–137.
- Rosenblad, C., Kirik, D., Devaux, B., Moffat, B., Phillips, H. S. and Bjorklund, A. (1999). Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. *Eur. J. Neurosci.* **11**, 1554–1566.
- Rosenblad, C., Gronborg, M., Hansen, C., Blom, N., Meyer, M., Johansen, J., Dago, L., Kirik, D., Patel, U. A., Lundberg, C. et al. (2000). In vivo protection of nigral dopamine neurons by lentiviral gene transfer of the novel GDNF-family member neublastin/artin. *Mol. Cell. Neurosci.* **15**, 199–214.
- Rouaux, C. and Arlotta, P. (2013). Direct lineage reprogramming of post-mitotic callosal neurons into corticofugal neurons in vivo. *Nat. Cell Biol.* **15**, 214–221.
- Roussa, E., von Bohlen und Halbach, O. and Kriegstein, K. (2009). TGF-beta in dopamine neuron development, maintenance and neuroprotection. *Adv. Exp. Med. Biol.* **651**, 81–90.
- Roy, N. S., Cleren, C., Singh, S. K., Yang, L., Beal, M. F. and Goldman, S. A. (2006). Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. *Nat. Med.* **12**, 1259–1268.
- Ryan, S. D., Dolatabadi, N., Chan, S. F., Zhang, X., Akhtar, M. W., Parker, J., Soldner, F., Sunico, C. R., Nagar, S., Talantova, M. et al. (2013). Isogenic human iPSC Parkinson's model shows nitrosative stress-induced dysfunction in MEF2-PGC1alpha transcription. *Cell* **155**, 1351–1364.
- Sacchetti, P., Sousa, K. M., Hall, A. C., Liste, I., Steffensen, K. R., Theofilopoulos, S., Parish, C. L., Hazenberg, C., Richter, L. A., Hovatta, O. et al. (2009). Liver X receptors and oxysterols promote ventral midbrain neurogenesis in vivo and in human embryonic stem cells. *Cell Stem Cell* **5**, 409–419.
- Sanchez, M. P., Silos-Santiago, I., Frisé, J., He, B., Lira, S. A. and Barbacid, M. (1996). Renal agenesis and the absence of enteric neurons in mice lacking GDNF. *Nature* **382**, 70–73.
- Sanchez-Danes, A., Consiglio, A., Richaud, Y., Rodriguez-Piza, I., Dehay, B., Edel, M., Bove, J., Memo, M., Vila, M., Raya, A. et al. (2012a). Efficient generation of A9 midbrain dopaminergic neurons by lentiviral delivery of LMX1A in human embryonic stem cells and induced pluripotent stem cells. *Hum. Gene Ther.* **23**, 56–69.
- Sanchez-Danes, A., Richaud-Patin, Y., Carballo-Carbajal, I., Jimenez-Delgado, S., Caig, C., Mora, S., Di Guglielmo, C., Ezquerro, M., Patel, B., Giralt, A. et al. (2012b). Disease-specific phenotypes in dopamine neurons from human iPSC-based models of genetic and sporadic Parkinson's disease. *EMBO Mol. Med.* **4**, 380–395.
- Sanchez-Pernaute, R., Studer, L., Bankiewicz, K. S., Major, E. O. and McKay, R. D. G. (2001). In vitro generation and transplantation of precursor-derived human dopamine neurons. *J. Neurosci. Res.* **65**, 284–288.
- Sanders, L. H., Laganière, J., Cooper, O., Mak, S. K., Vu, B. J., Huang, Y. A., Paschon, D. E., Vangipuram, M., Sundararajan, R., Urnov, F. D. et al. (2014). LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: reversal by gene correction. *Neurobiol. Dis.* **62**, 381–386.
- Sasaki, H., Hui, C., Nakafuku, M. and Kondoh, H. (1997). A binding site for Gli proteins is essential for HNF-3beta floor plate enhancer activity in transgenics and can respond to Shh in vitro. *Development* **124**, 1313–1322.
- Sato, T. and Nakamura, H. (2004). The Fgf8 signal causes cerebellar differentiation by activating the Ras-ERK signaling pathway. *Development* **131**, 4275–4285.
- Saucedo-Cardenas, O., Quintana-Hau, J. D., Le, W.-D., Smidt, M. P., Cox, J. J., De Mayo, F., Burbach, J. P. H. and Conneely, O. M. (1998). Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. *Proc. Natl. Acad. Sci. USA* **95**, 4013–4018.
- Schöndorf, D. C., Aureli, M., McAllister, F. E., Hindley, C. J., Mayer, F., Schmid, B., Sardi, S. P., Valsecchi, M., Hoffmann, S., Schwarz, L. K. et al. (2014). iPSC-derived neurons from GBA1-associated Parkinson's disease patients show autophagic defects and impaired calcium homeostasis. *Nat. Commun.* **5**, 4028.
- Seibler, P., Graziotto, J., Jeong, H., Simunovic, F., Klein, C. and Krainc, D. (2011). Mitochondrial Parkin recruitment is impaired in neurons derived from mutant PINK1 induced pluripotent stem cells. *J. Neurosci.* **31**, 5970–5976.
- Semina, E. V., Reiter, R. S. and Murray, J. C. (1997). Isolation of a new homeobox gene belonging to the Pitx/Rieg family: expression during lens development and mapping to the aphakia region on mouse chromosome 19. *Hum. Mol. Genet.* **6**, 2199–2116.
- Sharaf, A., Bock, H. H., Spittau, B., Bouché, E. and Kriegstein, K. (2013). ApoER2 and VLDLR are required for mediating reelin signalling pathway for normal migration and positioning of mesencephalic dopaminergic neurons. *PLoS ONE* **8**, e71091.

- Shimamura, K., Hirano, S., McMahon, A. P. and Takeichi, M. (1994). Wnt-1-dependent regulation of local E-cadherin and alpha N-catenin expression in the embryonic mouse brain. *Development* **120**, 2225–2234.
- Shults, C. W., Hashimoto, R., Brady, R. M. and Gage, F. H. (1990). Dopaminergic cells align along radial glia in the developing mesencephalon of the rat. *Neuroscience* **38**, 427–436.
- Smidt, M. P. and Burbach, J. P. H. (2007). How to make a mesodiencephalic dopaminergic neuron. *Nat. Rev. Neurosci.* **8**, 21–32.
- Smidt, M. P., van Schaick, H. S. A., Lancot, C., Tremblay, J. J., Cox, J. J., van der Kleij, A. A. M., Wolterink, G., Drouin, J. and Burbach, J. P. H. (1997). A homeodomain gene Ptx3 has highly restricted brain expression in mesencephalic dopaminergic neurons. *Proc. Natl. Acad. Sci. USA* **94**, 13305–13310.
- Smidt, M. P., Asbreuk, C. H. J., Cox, J. J., Chen, H., Johnson, R. L. and Burbach, J. P. (2000). A second independent pathway for development of mesencephalic dopaminergic neurons requires Lmx1b. *Nat. Neurosci.* **3**, 337–341.
- Smidt, M. P., Smits, S. M., Bouwmeester, H., Hamers, F. P. T., van der Linden, A. J. A., Hellemons, A. J. C. G. M., Graw, J. and Burbach, J. P. H. (2004). Early developmental failure of substantia nigra dopamine neurons in mice lacking the homeodomain gene Ptx3. *Development* **131**, 1145–1155.
- Smits, S. M., Ponnio, T., Conneely, O. M., Burbach, J. P. H. and Smidt, M. P. (2003). Involvement of Nurr1 in specifying the neurotransmitter identity of ventral midbrain dopaminergic neurons. *Eur. J. Neurosci.* **18**, 1731–1738.
- Soldner, F., Laganière, J., Cheng, A. W., Hockemeyer, D., Gao, Q., Alagappan, R., Khurana, V., Golbe, L. I., Myers, R. H., Lindquist, S. et al. (2011). Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. *Cell* **146**, 318–331.
- Sousa, K. M., Mira, H., Hall, A. C., Jansson-Sjöstrand, L., Kusakabe, M. and Arenas, E. (2007). Microarray analyses support a role for Nurr1 in resistance to oxidative stress and neuronal differentiation in neural stem cells. *Stem Cells* **25**, 511–519.
- Steinbeck, J. A., Choi, S. J., Mrejeru, A., Ganat, Y., Deisseroth, K., Sulzer, D., Mosharov, E. V. and Studer, L. (2015). Optogenetics enables functional analysis of human embryonic stem cell-derived grafts in a Parkinson's disease model. *Nat. Biotechnol.* **33**, 204–209.
- Stern, M. B., Marek, K. L., Friedman, J., Hauser, R. A., LeWitt, P. A., Tarsy, D. and Olanow, C. W. (2004). Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. *Mov. Disord.* **19**, 916–923.
- Stott, S. R. W., Metzakopian, E., Lin, W., Kaestner, K. H., Hen, R. and Ang, S. L. (2013). Foxa1 and foxa2 are required for the maintenance of dopaminergic properties in ventral midbrain neurons at late embryonic stages. *J. Neurosci.* **33**, 8022–8034.
- Su, Z., Niu, W., Liu, M.-L., Zou, Y. and Zhang, C.-L. (2014). In vivo conversion of astrocytes to neurons in the injured adult spinal cord. *Nat. Commun.* **5**, 3338.
- Sundberg, M., Bogetofte, H., Lawson, T., Jansson, J., Smith, G., Astradsson, A., Moore, M., Osborn, T., Cooper, O., Speakman, R. et al. (2013). Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons. *Stem Cells* **31**, 1548–1562.
- Suzuki-Hirano, A., Sato, T. and Nakamura, H. (2005). Regulation of isthmus Fgf8 signal by sprouty2. *Development* **132**, 257–265.
- Tagliavini, F., Pilleri, G., Bouras, C. and Constantinidis, J. (1984). The basal nucleus of Meynert in idiopathic Parkinson's disease. *Acta Neurol. Scand.* **70**, 20–28.
- Tailor, J., Kittappa, R., Leto, K., Gates, M., Borel, M., Paulsen, O., Spitzer, S., Karadottir, R. T., Rossi, F., Falk, A. et al. (2013). Stem cells expanded from the human embryonic hindbrain stably retain regional specification and high neurogenic potency. *J. Neurosci.* **33**, 12407–12422.
- Takahashi, K. and Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* **126**, 663–676.
- Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K. and Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* **131**, 861–872.
- Takaoka, K., Yamamoto, M. and Hamada, H. (2007). Origin of body axes in the mouse embryo. *Curr. Opin. Genet. Dev.* **17**, 344–350.
- Tang, M., Miyamoto, Y. and Huang, E. J. (2009). Multiple roles of beta-catenin in controlling the neurogenic niche for midbrain dopamine neurons. *Development* **136**, 2027–2038.
- Tang, M., Villaescusa, J. C., Luo, S. X., Guitarte, C., Lei, S., Miyamoto, Y., Taketo, M. M., Arenas, E. and Huang, E. J. (2010). Interactions of Wnt/beta-catenin signaling and sonic hedgehog regulate the neurogenesis of ventral midbrain dopamine neurons. *J. Neurosci.* **30**, 9280–9291.
- Theofilopoulos, S., Wang, Y., Kitambi, S. S., Sacchetti, P., Sousa, K. M., Bodin, K., Kirk, J., Saltó, C., Gustafsson, M., Toledo, E. M. et al. (2013). Brain endogenous liver X receptor ligands selectively promote midbrain neurogenesis. *Nat. Chem. Biol.* **9**, 126–133.
- Thomas, K. R. and Capecchi, M. R. (1990). Targeted disruption of the murine int-1 proto-oncogene resulting in severe abnormalities in midbrain and cerebellar development. *Nature* **346**, 847–850.
- Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., Waknitz, M. A., Swiergiel, J. J., Marshall, V. S. and Jones, J. M. (1998). Embryonic stem cell lines derived from human blastocysts. *Science* **282**, 1145–1147.
- Tomac, A., Lindqvist, E., Lin, L.-F. H., Ögren, S. O., Young, D., Hoffer, B. J. and Olson, L. (1995). Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. *Nature* **373**, 335–339.
- Torper, O., Pfisterer, U., Wolf, D. A., Pereira, M., Lau, S., Jakobsson, J., Bjorklund, A., Grealish, S. and Parmar, M. (2013). Generation of induced neurons via direct conversion in vivo. *Proc. Natl. Acad. Sci. USA* **110**, 7038–7043.
- Trupp, M., Arenas, E., Fainzilber, M., Nilsson, A.-S., Sieber, B.-A., Grigoriou, M., Kilkenny, C., Salazar-Gruoso, E., Pachnis, V., Arumäe, U. et al. (1996). Functional receptor for GDNF encoded by the c-ret proto-oncogene. *Nature* **381**, 785–789.
- van den Munckhof, P., Luk, K. C., Ste-Marie, L., Montgomery, J., Blanchet, P. J., Sadikot, A. F. and Drouin, J. (2003). Ptx3 is required for motor activity and for survival of a subset of midbrain dopaminergic neurons. *Development* **130**, 2535–2542.
- Veenivliet, J. V., dos Santos, M. T. M. A., Kouwenhoven, W. M., von Oerthel, L., Lim, J. L., van der Linden, A. J. A., Koerkamp, M. J. A. G., Holstege, F. C. P. and Smidt, M. P. (2013). Specification of dopaminergic subsets involves interplay of En1 and Ptx3. *Development* **140**, 3373–3384.
- Vierbuchen, T., Ostermeier, A., Pang, Z. P., Kokubu, Y., Südhof, T. C. and Wernig, M. (2010). Direct conversion of fibroblasts to functional neurons by defined factors. *Nature* **463**, 1035–1041.
- Villaescusa, J. C. and Arenas, E. (2010). Transplantable midbrain dopamine neurons: a moving target. *Exp. Neurol.* **222**, 173–178.
- Volpicelli, F., Caiazzo, M., Greco, D., Consales, C., Leone, L., Perrone-Capano, C., Colucci D'Amato, L. and di Porzio, U. (2007). Bdnf gene is a downstream target of Nurr1 transcription factor in rat midbrain neurons in vitro. *J. Neurochem.* **102**, 441–453.
- Volpicelli, F., De Gregorio, R., Pulcrano, S., Perrone-Capano, C., di Porzio, U. and Bellenchì, G. C. (2012). Direct regulation of Ptx3 expression by Nurr1 in culture and in developing mouse midbrain. *PLoS ONE* **7**, e30661.
- Voutilainen, M. H., Back, S., Porsti, E., Toppinen, L., Lindgren, L., Lindholm, P., Peranen, J., Saarna, M. and Tuominen, R. K. (2009). Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease. *J. Neurosci.* **29**, 9651–9659.
- Wagner, J., Akerud, P., Castro, D. S., Holm, P. C., Canals, J. M., Snyder, E. Y., Perlmann, T. and Arenas, E. (1999). Induction of a midbrain dopaminergic phenotype in Nurr1-overexpressing neural stem cells by type 1 astrocytes. *Nat. Biotechnol.* **17**, 653–659.
- Wallen, A., Castro, D. S., Zetterstrom, R. H., Karlen, M., Olson, L., Ericson, J. and Perlmann, T. (2001). Orphan nuclear receptor Nurr1 is essential for Ret expression in midbrain dopamine neurons and in the brain stem. *Mol. Cell. Neurosci.* **18**, 649–663.
- Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F. and Jaenisch, R. (2013). One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. *Cell* **153**, 910–918.
- Wapinski, O. L., Vierbuchen, T., Qu, K., Lee, Q. Y., Chanda, S., Fuentes, D. R., Giresi, P. G., Ng, Y. H., Marro, S., Neff, N. F. et al. (2013). Hierarchical mechanisms for direct reprogramming of fibroblasts to neurons. *Cell* **155**, 621–635.
- Wassarman, K. M., Lewandoski, M., Campbell, K., Joyner, A. L., Rubenstein, J. L., Martinez, S. and Martin, G. R. (1997). Specification of the anterior hindbrain and establishment of a normal mid/hindbrain organizer is dependent on Gbx2 gene function. *Development* **124**, 2923–2934.
- Weiner, W. J. (2004). Initial treatment of Parkinson disease: levodopa or dopamine agonists. *Arch. Neurol.* **61**, 1966–1969.
- Weinstein, D. C., Ruiz i Altaba, A., Chen, W. S., Hoodless, P., Prezioso, V. R., Jessell, T. M. and Darnell, J. E. Jr. (1994). The winged-helix transcription factor HNF-3 beta is required for notochord development in the mouse embryo. *Cell* **78**, 575–588.
- Xi, J., Liu, Y., Liu, H., Chen, H., Emborg, M. E. and Zhang, S.-C. (2012). Specification of midbrain dopamine neurons from primate pluripotent stem cells. *Stem Cells* **30**, 1655–1663.
- Xia, X. and Wong, S. T. (2012). Concise review: a high-content screening approach to stem cell research and drug discovery. *Stem Cells* **30**, 1800–1807.
- Xu, B., Goldman, J. S., Rymar, V. V., Forget, C., Lo, P. S., Bull, S. J., Vereker, E., Barker, P. A., Trudeau, L. E., Sadikot, A. F. et al. (2010). Critical roles for the netrin receptor deleted in colorectal cancer in dopaminergic neuronal precursor migration, axon guidance, and axon arborization. *Neuroscience* **169**, 932–949.
- Xue, Y., Ouyang, K., Huang, J., Zhou, Y., Ouyang, H., Li, H., Wang, G., Wu, Q., Wei, C., Bi, Y. et al. (2013). Direct conversion of fibroblasts to neurons by reprogramming PTB-regulated microRNA circuits. *Cell* **152**, 82–96.
- Yan, C. H., Levesque, M., Claxton, S., Johnson, R. L. and Ang, S.-L. (2011). Lmx1a and Lmx1b function cooperatively to regulate proliferation, specification, and differentiation of midbrain dopaminergic progenitors. *J. Neurosci.* **31**, 12413–12425.
- Yang, J., Brown, A., Ellisor, D., Paul, E., Hagan, N. and Zervas, M. (2013a). Dynamic temporal requirement of Wnt1 in midbrain dopamine neuron development. *Development* **140**, 1342–1352.

- Yang, S., Edman, L. C., Sanchez-Alcaniz, J. A., Fritz, N., Bonilla, S., Hecht, J., Uhlen, P., Pleasure, S. J., Villaescusa, J. C., Marin, O. et al. (2013b). Cxcl12/Cxcr4 signaling controls the migration and process orientation of A9-A10 dopaminergic neurons. *Development* **140**, 4554–4564.
- Ye, W., Shimamura, K., Rubenstein, J. L. R., Hynes, M. A. and Rosenthal, A. (1998). FGF and Shh signals control dopaminergic and serotonergic cell fate in the anterior neural plate. *Cell* **93**, 755–766.
- Yoo, A. S., Sun, A. X., Li, L., Shcheglovitov, A., Portmann, T., Li, Y., Lee-Messer, C., Dolmetsch, R. E., Tsien, R. W. and Crabtree, G. R. (2011). MicroRNA-mediated conversion of human fibroblasts to neurons. *Nature* **476**, 228–231.
- Zeng, X., Cai, J., Chen, J., Luo, Y., You, Z. B., Fotter, E., Wang, Y., Harvey, B., Miura, T., Backman, C. et al. (2004). Dopaminergic differentiation of human embryonic stem cells. *Stem Cells* **22**, 925–940.
- Zervas, M., Millet, S., Ahn, S. and Joyner, A. L. (2004). Cell behaviors and genetic lineages of the mesencephalon and rhombomere 1. *Neuron* **43**, 345–357.
- Zetterström, R. H., Williams, R., Perlmann, T. and Olson, L. (1996). Cellular expression of the immediate early transcription factors Nurr1 and NGFI-B suggests a gene regulatory role in several brain regions including the nigrostriatal dopamine system. *Brain Res. Mol. Brain Res.* **41**, 111–120.
- Zetterström, R. H., Solomin, L., Jansson, L., Hoffer, B. J., Olson, L. and Perlmann, T. (1997). Dopamine neuron agenesis in Nurr1-deficient mice. *Science* **276**, 248–250.
- Zhang, J., Pho, V., Bonasera, S. J., Holtzman, J., Tang, A. T., Hellmuth, J., Tang, S., Janak, P. H., Tecott, L. H. and Huang, E. J. (2007). Essential function of HIPK2 in TGFbeta-dependent survival of midbrain dopamine neurons. *Nat. Neurosci.* **10**, 77–86.
- Zou, J., Maeder, M. L., Mali, P., Pruett-Miller, S. M., Thibodeau-Beganny, S., Chou, B.-K., Chen, G., Ye, Z., Park, I.-H., Daley, G. Q. et al. (2009). Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. *Cell Stem Cell* **5**, 97–110.